<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Aminoadamantanes versus other antiviral drugs for chronic hepatitis C - Lamers, MH - 2014 | Cochrane Library</title> <meta content="Aminoadamantanes versus other antiviral drugs for chronic hepatitis C - Lamers, MH - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011132.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Aminoadamantanes versus other antiviral drugs for chronic hepatitis C - Lamers, MH - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011132.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011132.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Aminoadamantanes versus other antiviral drugs for chronic hepatitis C" name="citation_title"/> <meta content="Mieke H Lamers" name="citation_author"/> <meta content="m.lamers@mdl.umcn.nl" name="citation_author_email"/> <meta content="Mark Broekman" name="citation_author"/> <meta content="Radboud University Medical Center Nijmegen" name="citation_author_institution"/> <meta content="Joost PH Drenth" name="citation_author"/> <meta content="Radboud University Medical Center Nijmegen" name="citation_author_institution"/> <meta content="Christian Gluud" name="citation_author"/> <meta content="Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD011132.pub2" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/06/17" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011132.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011132.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011132.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Amantadine [*therapeutic use]; Antiviral Agents [*therapeutic use]; Hepatitis C, Chronic [*drug therapy]; Interferon‐alpha [therapeutic use]; Interferon‐gamma [therapeutic use]; Mycophenolic Acid [analogs &amp; derivatives, therapeutic use]; Randomized Controlled Trials as Topic; Ribavirin [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011132.pub2&amp;doi=10.1002/14651858.CD011132.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011132.pub2&amp;doi=10.1002/14651858.CD011132.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011132.pub2&amp;doi=10.1002/14651858.CD011132.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011132.pub2&amp;doi=10.1002/14651858.CD011132.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011132.pub2&amp;doi=10.1002/14651858.CD011132.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011132.pub2&amp;doi=10.1002/14651858.CD011132.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011132.pub2&amp;doi=10.1002/14651858.CD011132.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011132.pub2&amp;doi=10.1002/14651858.CD011132.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011132.pub2&amp;doi=10.1002/14651858.CD011132.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011132.pub2&amp;doi=10.1002/14651858.CD011132.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011132.pub2&amp;doi=10.1002/14651858.CD011132.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011132.pub2&amp;doi=10.1002/14651858.CD011132.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011132.pub2&amp;doi=10.1002/14651858.CD011132.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011132.pub2&amp;doi=10.1002/14651858.CD011132.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011132.pub2&amp;doi=10.1002/14651858.CD011132.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011132.pub2&amp;doi=10.1002/14651858.CD011132.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011132.pub2&amp;doi=10.1002/14651858.CD011132.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011132.pub2&amp;doi=10.1002/14651858.CD011132.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011132.pub2&amp;doi=10.1002/14651858.CD011132.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011132.pub2&amp;doi=10.1002/14651858.CD011132.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011132.pub2&amp;doi=10.1002/14651858.CD011132.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011132.pub2&amp;doi=10.1002/14651858.CD011132.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011132.pub2&amp;doi=10.1002/14651858.CD011132.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="qy4lqFNF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011132\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011132\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011132\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011132\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011132.pub2",title:"Aminoadamantanes versus other antiviral drugs for chronic hepatitis C",firstPublishedDate:"Jun 17, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Hepato‐Biliary Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=qy4lqFNF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011132.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011132.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011132.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011132.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011132.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011132.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011132.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011132.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011132.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011132.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>435 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011132.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011132.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011132.pub2/full#CD011132-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011132.pub2/full#CD011132-sec-0085"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011132.pub2/full#CD011132-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011132.pub2/full#CD011132-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011132.pub2/full#CD011132-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011132.pub2/full#CD011132-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011132.pub2/full#CD011132-sec-0061"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011132.pub2/full#CD011132-sec-0079"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011132.pub2/appendices#CD011132-sec-0090"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/table_n/CD011132StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/table_n/CD011132StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011132.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011132.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011132.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011132.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011132.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011132.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Aminoadamantanes versus other antiviral drugs for chronic hepatitis C</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011132.pub2/information#CD011132-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Mieke H Lamers</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011132.pub2/information#CD011132-cr-0003">Mark Broekman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011132.pub2/information#CD011132-cr-0004">Joost PH Drenth</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011132.pub2/information#CD011132-cr-0005">Christian Gluud</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/information/en#CD011132-sec-0093">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 17 June 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011132.pub2">https://doi.org/10.1002/14651858.CD011132.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011132-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011132-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011132-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011132-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011132-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011132-abs-0001" lang="en"> <section id="CD011132-sec-0001"> <h3 class="title" id="CD011132-sec-0001">Background</h3> <p>Hepatitis C virus infection affects around 3% of the world population or approximately 160 million people. A variable proportion (5% to 40%) of the infected people develop clinical symptoms. Hence, hepatitis C virus is a leading cause of liver‐related morbidity and mortality with hepatic fibrosis, end‐stage liver cirrhosis, and hepatocellular carcinoma as the dominant clinical sequelae. Combination therapy with pegylated (peg) interferon‐alpha and ribavirin achieves sustained virological response (that is, undetectable hepatitis C virus RNA in serum by sensitivity testing six months after the end of treatment) in approximately 40% to 80% of treated patients, depending on viral genotype. Recently, a new class of drugs have emerged for hepatitis C infection, the direct acting antivirals, which in combination with standard therapy or alone can lead to sustained virological response in 80% or more of treated patients. Aminoadamantanes, mostly amantadine, are antiviral drugs used for the treatment of patients with chronic hepatitis C. We have previously systematically reviewed amantadine versus placebo or no intervention and found no significant effects of the amantadine on all‐cause mortality or liver‐related morbidity and on adverse events in patients with hepatitis C. Overall, we did not observe a significant effect of amantadine on sustained virological response. In this review, we systematically review aminoadamantanes versus other antiviral drugs. </p> </section> <section id="CD011132-sec-0002"> <h3 class="title" id="CD011132-sec-0002">Objectives</h3> <p>To assess the beneficial and harmful effects of aminoadamantanes versus other antiviral drugs for patients with chronic hepatitis C virus infection by conducting a systematic review with meta‐analyses and trial sequential analyses of randomised clinical trials. </p> </section> <section id="CD011132-sec-0003"> <h3 class="title" id="CD011132-sec-0003">Search methods</h3> <p>The Cochrane Hepato‐Biliary Group Controlled Trials Register (1996 to December 2013)<b>,</b> the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 11 of 12, 2013), MEDLINE (1946 to December 2013), EMBASE (1974 to December 2013), Science Citation Index EXPANDED (1900 to December 2013), the WHO International Clinical Trials Registry Platform (<a href="http://www.who.int/ictrp" target="_blank">www.who.int/ictrp</a>), Google Scholar, and Eudrapharm up to December 2013. Furthermore, full text searches were conducted until December 2013. </p> </section> <section id="CD011132-sec-0004"> <h3 class="title" id="CD011132-sec-0004">Selection criteria</h3> <p>Randomised clinical trials assessing aminoadamantanes in participants with chronic hepatitis C virus infection. </p> </section> <section id="CD011132-sec-0005"> <h3 class="title" id="CD011132-sec-0005">Data collection and analysis</h3> <p>Two authors independently extracted data. RevMan Analysis was used for statistical analysis of dichotomous data using risk ratio (RR) with 95% confidence intervals (CI). Methodological domains were used to assess the risk of systematic errors ('bias'). We used trial sequential analysis to assess risk of random errors ('play of chance'). </p> </section> <section id="CD011132-sec-0006"> <h3 class="title" id="CD011132-sec-0006">Main results</h3> <p>Six randomised clinical trials with 581 participants with chronic hepatitis C were included. All trials had high risk of bias. The included trials compared amantadine versus other antiviral drugs: ribavirin, mycophenolate mofetil, interferon‐alpha, or interferon‐gamma. Standard antiviral therapy (interferon‐alpha, interferon‐alpha plus ribavirin, or peg interferon alpha) was administered equally to the intervention and the control groups in five trials, depending on when the trial was conducted. <i>Four trials compared amantadine versus ribavirin</i> . There were no deaths or liver‐related morbidity in the two intervention groups (0/216 (0%) versus 0/211 (0%); 4 trials; very low quality of the evidence). The lower estimated risk for (serious) adverse events leading to treatment discontinuation with amantadine was imprecise (RR 0.56, 95% CI 0.27 to 1.16; based on 10/216 (5%) versus 18/211 (9%) participants in 4 trials; very low quality of the evidence). There were more participants with failure of sustained virological response in the amantadine group than in the ribavirin group (206/216 (96%) versus 176/211 (84%); RR 1.14, 95% CI 1.07 to 1.22, 4 trials; low quality of the evidence). Amantadine versus ribavirin more often failed to achieve end‐of follow‐up biochemical response (41/46 (89%) versus 31/46 (67%); RR 1.31, 95% CI 1.05 to 1.63; 2 trials; very low quality of the evidence). <i>One trial compared amantadine versus mycophenolate mofetil</i> . There were no significant differences between the two treatment groups, except that amantadine was inferior to mycophenolate mofetil regarding the outcome failure to achieve end‐of treatment virological response (low quality of evidence). <i>One trial each compared amantadine versus interferon‐alpha or interferon‐gamma</i>. Both comparisons showed no significant differences in the treatment outcomes (very low quality of the evidence). The observed effects could be due to real effects, systematic errors (bias), or random errors (play of chance). This possible influence on the observed effect by play of chance is due to the fact that trial sequential analyses could not confirm our findings. We were not able to perform meta‐analyses on failure of histological improvement and quality of life due to lack of valid data in all trial comparisons. </p> </section> <section id="CD011132-sec-0007"> <h3 class="title" id="CD011132-sec-0007">Authors' conclusions</h3> <p>This systematic review has identified evidence of very low quality for the key outcomes of all‐cause mortality or liver‐related morbidity and adverse events in people with chronic hepatitis C when treated with amantadine compared with ribavirin, mycophenolate, interferon‐alpha, or interferon‐gamma. The timeframe for measuring the composite outcome was insufficient in the included trials. There was low quality evidence that amantadine led to more participants who failed to achieve sustained virological response compared with ribavirin. This observation may be real or caused by systematic errors (bias), but it does not seem to be caused by random error (play of chance). Due to the low quality of the evidence, we are unable to determine definitively whether amantadine is less effective than other antivirals in patients with chronic hepatitis C. As it appears less likely that future trials assessing amantadine or potentially other aminoadamantanes for patients with chronic hepatitis C would show strong benefits, it is probably better to focus on the assessments of other direct acting antiviral drugs. We found no evidence assessing other aminoadamantanes in randomised clinical trials in order to recommend or refute their use. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011132-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011132-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011132-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011132-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011132-abs-0005">Français</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011132-abs-0004" lang="en"> <h3>Aminoadamantanes versus other antiviral drugs for chronic hepatitis C</h3> <p><b>Background</b> </p> <p>Hepatitis C virus is mainly transmitted by contact to infected blood. Chronic hepatitis C infection affects around 3% of the world population and progresses slowly. Most patients present without symptoms, or with symptoms like fatigue or liver‐related morbidity. Frequently, the disease is discovered by coincidence because of abnormal laboratory results. Around 5% to 40% of all infected patients will develop severe liver damage which can cause severe liver‐related morbidities and eventually death. Current treatment consists of pegylated interferon‐alpha plus ribavirin and in some subgroups of patients these agents are combined with telaprevir or boceprevir, or other direct acting antivirals. In about 70% of patients with chronic hepatitis C, it is possible to eradicate the virus from the blood, but the clinical effects are not known. Aminoadamantanes (another group of antiviral drugs), mostly amantadine, have been tested in several clinical trials. The authors have previously systematically reviewed amantadine versus placebo or no intervention and found no significant effects of amantadine. </p> <p><b>Review questions and study characteristics</b> </p> <p>Only amantadine has been tested in randomised clinical trials including participants with chronic hepatitis C. The main goal of these trials was to investigate whether amantadine as a single therapy or amantadine in combination with other antiviral therapies, compared with placebo or no intervention (with or without antiviral therapy), could increase the proportion of patients with virus eradication from the blood. This review evaluates whether amantadine versus other antiviral drugs has any beneficial or harmful effect in patients with chronic hepatitis C. The trials compared amantadine with ribavirin, mycophenolate mofetil, interferon‐alpha, or interferon‐gamma. The primary outcomes were the composite of all‐cause mortality or liver‐related morbidity and adverse events. This review includes six randomised clinical trials with a total of 581 patients. </p> <p><b>Key results and quality of evidence</b> </p> <p>All the included trials were with high risk of bias. This review did not demonstrate any benefits or harms of amantadine on all‐cause mortality or liver‐related morbidity and on adverse events, but data were sparse. <i>Compared with ribavirin</i> , amantadine seemed to lead to more participants who fail to achieve sustained virological response (that is, undetectable hepatitis C virus RNA in serum by sensitivity testing six months after the end of treatment). This may be real or due to bias (systematic errors), but it does not seem to be due to play of chance (random errors), as trial sequential analysis confirmed the result. <i>Compared with mycophenolate mofetil</i> , amantadine seemed less effective in achieving end‐of‐treatment virological response. <i>Compared with interferon‐alpha or interferon‐gamma</i>, amantadine did not seem to offer benefits. Accordingly, the evidence from this review does not support the routine clinical use of amantadine. Therefore, it is probably better to examine the effects of other direct acting antivirals in the hepatitis C field than to conduct more randomised clinical trials on amantadine. We found no randomised clinical trials assessing other aminoadamantanes, for example rimantadine. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011132-sec-0085" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011132-sec-0085"></div> <h3 class="title" id="CD011132-sec-0086">Implications for practice</h3> <section id="CD011132-sec-0086"> <p>This review shows that there seems to be no significant benefit of amantadine on hepatitis C virus‐infected patients for all‐cause mortality or liver‐related morbidity, or on adverse events in hepatitis C‐infected patients; although the timeframe for measuring the composite outcome was insufficient in the included randomised clinical trials. Furthermore, amantadine did not decrease the proportion of patients with failure to achieve sustained virological response compared with ribavirin. In the absence of convincing evidence of benefit, the use of amantadine seems only justified in the context of randomised clinical trials assessing the effects of combination therapy with peg interferon‐alpha and ribavirin. We found no randomised clinical trials assessing other aminoadamantanes. </p> </section> <h3 class="title" id="CD011132-sec-0087">Implications for research</h3> <section id="CD011132-sec-0087"> <p>Given the results of our analysis, we cannot conclude whether new randomised clinical trials will or will not find any beneficial effect of amantadine on patients' survival in chronic hepatitis C patients. We found no evidence for other aminoadamantanes. Based on the results of the overall evidence, it appears less likely that future trials assessing amantadine or potentially other aminoadamantanes for patients with chronic hepatitis C would show strong benefits. Therefore, it is probably better to focus on the assessments of other direct acting antiviral drugs. To our knowledge, no ongoing trials investigate the effects of amantadine in hepatitis C‐infected patients. Any further trials ought to be conducted and reported according to the SPIRIT and CONSORT guidelines (<a href="./references#CD011132-bbs2-0084" title="SchulzKF , AltmanDG , MoherD , for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Internal Journal of Surgery2011;9(8):672‐7. ">Schulz 2012</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011132-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011132-sec-0022"></div> <div class="table" id="CD011132-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Aminoadamantanes compared with ribavirin for chronic hepatitis C</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with chronic hepatitis C. </p> <p><b>Settings:</b> mainly outpatients in tertiary and teaching hospitals. </p> <p><b>Intervention:</b> aminoadamantanes. </p> <p><b>Comparison:</b> ribavirin. </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ribavirin</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Aminoadamantanes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality or liver‐related morbidity</b> </p> <p>Follow‐up: 12‐24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.98</b> </p> <p>(0.00 to 248.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>427<br/> (4 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 12‐24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.56</b> </p> <p>(0.27 to 1.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>427<br/> (4 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>86 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>47 per 1000</b> <br/> (23 to 98) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Failure of sustained virological response</b> </p> <p>Absence of clearance of HCV RNA from the blood 6 months after treatment</p> <p>Follow‐up: 12‐24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.14</b> </p> <p>(1.07 to 1.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>427<br/> (4 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>low<sup>2</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>835 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>954 per 1000</b> <br/> (896 to 1021) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Failure of end of treatment virological response</b> </p> <p>Absence of clearance of HCV RNA from the blood at end of treatment</p> <p>Follow‐up: 12‐24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.20</b> </p> <p>(1.05 to 1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>309</p> <p>(3 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>2</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>678 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>816 per 1000</b> <br/> (714 to 925) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Failure of normalisation of ALT at end of treatment</b> </p> <p>Follow‐up: 12‐24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.02</b> </p> <p>(1.07 to 3.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>29<br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>429 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>867 per 1000</b> <br/> (460 to 1640) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Failure of normalisation of ALT at end of follow‐up</b> </p> <p>Follow‐up: 12‐24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.31</b> </p> <p>(1.05 to 1.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>92<br/> (2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>674 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>892 per 1000</b> <br/> (715 to 1110) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ALT:</b> alanine aminotransferase; <b>CI:</b> confidence interval; <b>HCV:</b> hepatitis C virus; <b>RNA:</b> ribonucleic acid; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>1. Quality of the evidence was downgraded based on the risk of bias, imprecision of results, inconsistency of results.<br/> 2. Quality of the evidence was downgraded based on the risk of bias and inconsistency of results. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011132-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011132-sec-0023"></div> <section id="CD011132-sec-0024"> <h3 class="title" id="CD011132-sec-0024">Description of the condition</h3> <p>Hepatitis C virus was first described in 1989 (<a href="./references#CD011132-bbs2-0026" title="ChooQL , KuoG , WeinerAJ , OverbyLR , BradleyDW , HoughtonM . Isolation of a cDNA clone derived from a blood‐borne non‐A, non‐B viral hepatitis genome. Science1989;244(4902):359‐62. ">Choo 1989</a>). It affects around 3% of the world population, thus affecting approximately 160 million people (<a href="./references#CD011132-bbs2-0094" title="SyT , JamalMM . Epidemiology of hepatitis C virus (HCV) infection. International Journal of Medical Sciences2006;3(2):41‐6. ">Sy 2006</a>; <a href="./references#CD011132-bbs2-0065" title="LavanchyD . Evolving epidemiology of hepatitis C virus. Clinical Microbiology and Infection2011;17(2):107‐15. ">Lavanchy 2011</a>). Hepatitis C virus is a leading cause of mortality and liver‐related morbidity with hepatic fibrosis, liver cirrhosis, and hepatocellular carcinoma as the dominant clinical sequelae (<a href="./references#CD011132-bbs2-0094" title="SyT , JamalMM . Epidemiology of hepatitis C virus (HCV) infection. International Journal of Medical Sciences2006;3(2):41‐6. ">Sy 2006</a>). Hepatocellular carcinoma occurs in 3 per 100,000 persons in the United States of America (<a href="./references#CD011132-bbs2-0040" title="El‐SeragHB , DavilaJA , PetersenNJ , McGlynnKA . The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Annals of Internal Medicine2003;139(10):817‐23. ">El‐Serag 2003</a>). Hepatitis C virus is responsible for one‐third of these hepatocellular carcinomas (<a href="./references#CD011132-bbs2-0040" title="El‐SeragHB , DavilaJA , PetersenNJ , McGlynnKA . The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Annals of Internal Medicine2003;139(10):817‐23. ">El‐Serag 2003</a>). In cirrhotic hepatitis C virus patients, the annual occurrence of hepatocellular carcinoma is 1% to 4% (<a href="./references#CD011132-bbs2-0064" title="LauerGM , WalkerBD . Hepatitis C virus infection. New England Journal of Medicine2001;345(1):41‐52. ">Lauer 2001</a>). Furthermore, hepatitis C virus infection is the most common indication for orthotopic liver transplantation (<a href="./references#CD011132-bbs2-0057" title="KimWR , TerraultNA , PedersenRA , TherneauTM , EdwardsE , HindmanAA , et al. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology2009;137(5):1680‐6. ">Kim 2009</a>). </p> <p>Chronic hepatitis C virus progresses slowly, over a time frame of 15 years to 50 years. Prospective and retrospective studies following cohorts of patients for decades suggested that less than 10% of all infected individuals would develop end‐stage liver disease. However, there are also publications reporting on patients who had developed cirrhosis two or three decades after infection with a range of 0.5% to 39% (<a href="./references#CD011132-bbs2-0061" title="KoretzRL , AbbeyH , ColemanE , GitnickG . Non‐A, non‐B post‐transfusion hepatitis. Lookin back in the second decade. Annals of Internal Medicine1993;119(2):110‐5. ">Koretz 1993</a>; <a href="./references#CD011132-bbs2-0055" title="Kenny‐WalshE . Clinical outcomes after hepatitis C infection from contaminated anti‐D immune globulin. Irish Hepatology Research Group. New England Journal of Medicine1999;340(16):1228‐33. ">Kenny‐Walsh 1999</a>; <a href="./references#CD011132-bbs2-0079" title="RodgerAJ , RobertsS , LaniganA , BowdenS , BrownT , CroftsN . Assessment of long‐term outcomes of community‐acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology2000;32(3):582‐7. ">Rodger 2000</a>; <a href="./references#CD011132-bbs2-0102" title="WieseM , BerrF , LafrenzM , PorstH , OesenU . Low frequency of cirrhosis in a hepatitis C (genotype 1b) single‐source outbreak in Germany: a 20‐year multicenter study. Hepatology2000;32(1):91‐6. ">Wiese 2000</a>; <a href="./references#CD011132-bbs2-0095" title="TheinHH , YiQ , DoreGJ , KrahnMD . Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection: a meta‐analysis and meta‐regression. Hepatology2008;48(2):418‐31. ">Thein 2008</a>; <a href="./references#CD011132-bbs2-0085" title='SeeffLB . The history of the "natural history" of hepatitis C (1968‐2009). Liver International2009;29 Suppl 1:89‐99. '>Seeff 2009</a>). </p> <p>Hepatitis C virus is divided into six genotypes (from 1 to 6) (<a href="./references#CD011132-bbs2-0088" title="SimmondsP , BukhJ , CombetC , DeleageG , EnomotoN , FeinstoneS , et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology2005;42(4):962‐73. ">Simmonds 2005</a>). Genotypes 1 to 4 are the most common genotypes (<a href="./references#CD011132-bbs2-0088" title="SimmondsP , BukhJ , CombetC , DeleageG , EnomotoN , FeinstoneS , et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology2005;42(4):962‐73. ">Simmonds 2005</a>). Several factors have an influence on achieving a sustained virological response to antiviral drugs (that is, undetectable hepatitis C virus ribonucleic acid (RNA) in serum by sensitivity testing six months after the end of treatment); genotype is one of these factors (<a href="./references#CD011132-bbs2-0017" title="AsselahT , EstrabaudE , BiecheI , LapalusM , DeMuynckS , VidaudM , et al. Hepatitis C: viral and host factors associated with non‐response to pegylated interferon plus ribavirin. Liver International 210;30(9):1259‐69. ">Asselah 2010</a>). Genotypes 2 and 3 respond better to treatment than genotypes 1 and 4 (<a href="./references#CD011132-bbs2-0017" title="AsselahT , EstrabaudE , BiecheI , LapalusM , DeMuynckS , VidaudM , et al. Hepatitis C: viral and host factors associated with non‐response to pegylated interferon plus ribavirin. Liver International 210;30(9):1259‐69. ">Asselah 2010</a>). </p> <p>In 1990, interferon‐alpha, an antiviral drug, was approved for the treatment of chronic hepatitis C virus as monotherapy (<a href="./references#CD011132-bbs2-0097" title="TineF , MagrinS , CraxiA , PagliaroL . Interferon for non‐A, non‐B chronic hepatitis. A meta‐analysis of randomised clinical trials. Journal of Hepatology1991;13(2):192‐9. ">Tine 1991</a>). Interferon‐alpha was administered subcutaneously in doses of equal to or more than three million units (MU) in the induction phase (during one to three months) and less than three MU in the maintenance phase (<a href="./references#CD011132-bbs2-0097" title="TineF , MagrinS , CraxiA , PagliaroL . Interferon for non‐A, non‐B chronic hepatitis. A meta‐analysis of randomised clinical trials. Journal of Hepatology1991;13(2):192‐9. ">Tine 1991</a>). Results of studies showed that only 10% to 17% of patients responded to interferon‐alpha monotherapy in achieving a sustained virological response compared with 1% to 3% of participants on no intervention (<a href="./references#CD011132-bbs2-0030" title="DavisGL , BalartLA , SchiffER , LindsayK , BodenheimerHCJr , PerrilloRP , et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. New England Journal of Medicine1989;321(22):1501‐6. ">Davis 1989</a>; <a href="./references#CD011132-bbs2-0072" title="MyersRP , RegimbeauC , ThevenotT , LeroyV , MathurinP , OpolonP , et al. Interferon for interferon naive patients with chronic hepatitis C. Cochrane Database of Systematic Reviews2002, Issue 2. [DOI: 10.1002/14651858.CD000370] ">Myers 2002</a>). </p> <p>Antiviral drugs for patients with hepatitis C virus‐related liver disease have improved considerably during the past two decades (<a href="./references#CD011132-bbs2-0041" title="GhanyMG , StraderDB , ThomasDL , SeeffLB . Diagnosis, management, and treatment of hepatitis C: an update. Hepatology2009;49(4):1335‐74. ">Ghany 2009</a>). In 1998, trials assessed the combination of interferon‐alpha and ribavirin compared with interferon alpha alone (<a href="./references#CD011132-bbs2-0031" title="DavisGL , Esteban‐MurR , RustgiV , HoefsJ , GordonSC , TrepoC , et al. Interferon alfa‐2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. New England Journal of Medicine1998;339(21):1493‐9. ">Davis 1998</a>; <a href="./references#CD011132-bbs2-0070" title="McHutchisonJG , GordonSC , SchiffER , ShiffmanML , LeeWM , RustgiVK , et al. Interferon alfa‐2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. New England Journal of Medicine1998;339(21):1485‐92. ">McHutchison 1998</a>; <a href="./references#CD011132-bbs2-0075" title="PoynardT , MarcellinP , LeeSS , NiederauC , MinukGS , IdeoG , et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet1998;352(9138):1426‐32. ">Poynard 1998</a>). This combination treatment resulted in an improved antiviral response in naive, chronic hepatitis C virus‐infected patients compared with interferon‐alpha alone (<a href="./references#CD011132-bbs2-0023" title="BrokJ , GluudLL , GluudC . Ribavirin plus interferon versus interferon for chronic hepatitis C. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD005445.pub2] ">Brok 2010</a>), and in previously treated patients who had failed to respond to interferon‐alpha monotherapy (<a href="./references#CD011132-bbs2-0023" title="BrokJ , GluudLL , GluudC . Ribavirin plus interferon versus interferon for chronic hepatitis C. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD005445.pub2] ">Brok 2010</a>). </p> <p>The success of antiviral therapy is usually defined as the proportion of patients who achieve sustained virological response, that is, clearance of hepatitis C virus RNA from the blood six months after treatment. Observational studies have suggested that people with sustained virological response have less disease progression and less risk of hepatocellular carcinoma (<a href="./references#CD011132-bbs2-0098" title="UenoY , SollanoJD , FarrellGC . Prevention of hepatocellular carcinoma complicating chronic hepatitis C. Journal of Gastroenterology and Hepatology2009;24(4):531‐6. ">Ueno 2009</a>). However, following a systematic review of meta‐analyses with randomised clinical trials comparing ribavirin plus interferon‐alpha versus interferon‐alpha alone, this drug therapy combination seemed to result in more patients with a sustained virological response, but no conclusion could be made if this combination results in less mortality or morbidity (<a href="./references#CD011132-bbs2-0023" title="BrokJ , GluudLL , GluudC . Ribavirin plus interferon versus interferon for chronic hepatitis C. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD005445.pub2] ">Brok 2010</a>). Sustained virological response is still a non‐validated putative surrogate outcome measure (<a href="./references#CD011132-bbs2-0043" title="GluudC , BrokJ , GongY , KoretzRL . Hepatology may have problems with putative surrogate outcome measures. Journal of Hepatology2007;46(4):734‐42. [PUBMED: 17316871] ">Gluud 2007</a>). </p> <p>A recent trial showed that there was an increased mortality in patients who were retreated with interferon‐alpha compared with non‐treated patients (<a href="./references#CD011132-bbs2-0036" title="DiBisceglieAM , StoddardAM , DienstagJL , ShiffmanML , SeeffLB , BonkovskyHL , et al. Excess mortality in patients with advanced chronic hepatitis C treated with long‐term peginterferon. Hepatology2011;53(4):1100‐8. [PUBMED: 21480316] ">Di Bisceglie 2011</a>) and that was supported in a Cochrane systematic review (<a href="./references#CD011132-bbs2-0062" title="KoretzRL , PleguezueloM , ArvanitiV , BaenaPB , CiriaR , GurusamyKS , et al. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD003617.pub2] ">Koretz 2013</a>). </p> <p>The current standard of treatment for chronic hepatitis C virus infection, according to guidelines, is a combination of pegylated interferon‐alpha (peg interferon‐alpha) and ribavirin (<a href="./references#CD011132-bbs2-0041" title="GhanyMG , StraderDB , ThomasDL , SeeffLB . Diagnosis, management, and treatment of hepatitis C: an update. Hepatology2009;49(4):1335‐74. ">Ghany 2009</a>; <a href="./references#CD011132-bbs2-0037" title="European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. Journal of Hepatology2014;60(2):392‐420. ">EASL 2014</a>). The regimen can include either peg interferon‐alpha‐2b (Peg‐Intron®, Schering Plough Corp., Kenilworth, NJ) or peg interferon‐alpha‐2a (Pegasys®, Hoffmann‐La Roche, Nutley, NJ), both of which are administered subcutaneously (<a href="./references#CD011132-bbs2-0018" title="AwadT , ThorlundK , HauserG , StimacD , MabroukM , GluudC . Peginterferon alpha‐2a is associated with higher sustained virological response than peginterferon alfa‐2b in chronic hepatitis C: systematic review of randomized trials. Hepatology2010;51(4):1176‐84. ">Awad 2010</a>). The optimal dose of peg interferon‐alpha‐2b is 1.5 µg/kg/week (<a href="./references#CD011132-bbs2-0018" title="AwadT , ThorlundK , HauserG , StimacD , MabroukM , GluudC . Peginterferon alpha‐2a is associated with higher sustained virological response than peginterferon alfa‐2b in chronic hepatitis C: systematic review of randomized trials. Hepatology2010;51(4):1176‐84. ">Awad 2010</a>; <a href="./references#CD011132-bbs2-0048" title="HauserG , AwadT , ThorlundK , ŠtimacD , MabroukM , GluudC . Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD005642.pub3] ">Hauser 2014a</a>). Peg interferon‐alpha‐2a is administered at a fixed dose of 180 µg weekly (<a href="./references#CD011132-bbs2-0018" title="AwadT , ThorlundK , HauserG , StimacD , MabroukM , GluudC . Peginterferon alpha‐2a is associated with higher sustained virological response than peginterferon alfa‐2b in chronic hepatitis C: systematic review of randomized trials. Hepatology2010;51(4):1176‐84. ">Awad 2010</a>). Ribavirin is an oral therapy with weight‐based total daily doses between 800 mg to 1200 mg administered twice per day (<a href="./references#CD011132-bbs2-0022" title="BrokJ , GluudLL , GluudC . Ribavirin monotherapy for chronic hepatitis C. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD005527.pub2] ">Brok 2009</a>). Between 40% and 80% of chronic hepatitis C virus patients without co‐infection with hepatitis B virus or human immunodeficiency virus (HIV) will achieve a sustained virological response after treatment with peg interferon‐alpha and ribavirin (<a href="./references#CD011132-bbs2-0087" title="SiminM , BrokJ , StimacD , GluudC , GluudLL . Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C. Alimentary Pharmacology &amp; Therapeutics2007;25(10):1153‐62. ">Simin 2007</a>; <a href="./references#CD011132-bbs2-0018" title="AwadT , ThorlundK , HauserG , StimacD , MabroukM , GluudC . Peginterferon alpha‐2a is associated with higher sustained virological response than peginterferon alfa‐2b in chronic hepatitis C: systematic review of randomized trials. Hepatology2010;51(4):1176‐84. ">Awad 2010</a>; <a href="./references#CD011132-bbs2-0047" title="HauserG , AwadT , BrokJ , ThorlundK , ŠtimacD , MabroukM , et al. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD005441.pub3] ">Hauser 2014</a>; <a href="./references#CD011132-bbs2-0048" title="HauserG , AwadT , ThorlundK , ŠtimacD , MabroukM , GluudC . Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD005642.pub3] ">Hauser 2014a</a>). </p> <p>Recently, a new class of antiviral drugs for hepatitis C virus have emerged on the market. These antiviral agents act directly, inhibiting the non structural (NS) NS3/N4A serine protease and NS5B polymerase inhibitors of hepatitis C virus. The direct acting antivirals can alone, or in concert with peg interferon‐alpha and ribavirin (triple therapy) increase sustained virological response proportions to 80% or above (<a href="./references#CD011132-bbs2-0019" title="BaconBR , GordonSC , LawitzE , MarcellinP , VierlingJM , ZeuzemS , et al. Boceprevir for previously treated chronic HCV genotype 1 infection. New England Journal of Medicine2011;364(13):1207‐17. [PUBMED: 21449784] ">Bacon 2011</a>; <a href="./references#CD011132-bbs2-0053" title="JacobsonIM , McHutchisonJG , DusheikoG , DiBisceglieAM , ReddyKR , BzowejNH , et al. Telaprevir for previously untreated chronic hepatitis C virus infection. New England Journal of Medicine2011;364(25):2405‐16. [PUBMED: 21696307] ">Jacobson 2011</a>; <a href="./references#CD011132-bbs2-0074" title="PoordadF , McConeJJr , BaconBR , BrunoS , MannsMP , SulkowskiMS , et al. Boceprevir for untreated chronic HCV genotype 1 infection. New England Journal of Medicine2011;364(13):1195‐206. [PUBMED: 21449783] ">Poordad 2011</a>; <a href="./references#CD011132-bbs2-0086" title="ShermanKE , FlammSL , AfdhalNH , NelsonDR , SulkowskiMS , EversonGT , et al. Response‐guided telaprevir combination treatment for hepatitis C virus infection. New England Journal of Medicine2011;365(11):1014‐24. [PUBMED: 21916639] ">Sherman 2011</a>; <a href="./references#CD011132-bbs2-0104" title="ZeuzemS , AndreoneP , PolS , LawitzE , DiagoM , RobertsS , et al. Telaprevir for retreatment of HCV infection. New England Journal of Medicine2011;364(25):2417‐28. [PUBMED: 21696308] ">Zeuzem 2011</a>; <a href="./references#CD011132-bbs2-0066" title="LawitzE , MangiaA , WylesD , Rodriguez‐TorresM , HassaneinT , GordonSC , et al. Sofosbuvir for previously untreated chronic hepatitis C infection. New England Journal of Medicine2013;368(20):1878‐87. [PUBMED: 23607594] ">Lawitz 2013</a>; <a href="./references#CD011132-bbs2-0067" title="LawitzE , PoordadFF , PangPS , HylandRH , DingX , MoH , et al. Sofosbuvir and ledipasvir fixed‐dose combination with and without ribavirin in treatment‐naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open‐label, randomised, phase 2 trial. Lancet2014;383(9916):515‐23. ">Lawitz 2014</a>; <a href="./references#CD011132-bbs2-0093" title="SulkowskiMS , GardinerDF , Rodriguez‐TorresM , ReddyKR , HassaneinT , JacobsonI , et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. New England Journal of Medicine2014;370(3):211‐21. ">Sulkowski 2014</a>). The effects they show on sustained virological response will hopefully lead to comparable clinical responses. </p> </section> <section id="CD011132-sec-0025"> <h3 class="title" id="CD011132-sec-0025">Description of the intervention</h3> <p>Aminoadamantanes is another antiviral drug group which includes amantadine and rimantadine. The drugs have been investigated in several studies for treatment of patients with chronic hepatitis C virus (<a href="./references#CD011132-bbs2-0020" title="BrillantiS , FoliM , DiTomasoM , GramantieriL , MasciC , BolondiL . Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non‐responders. Italian Journal of Gastroenterology and Hepatology1999;31(2):130‐4. [PUBMED: 10363198] ">Brillanti 1999</a>; <a href="./references#CD011132-bbs2-0089" title="SmithJP , RileyTR3rd , DevenyiA , BingamanSI , KunselmanA . Amantadine therapy for chronic hepatitis C. Journal of General Internal Medicine2004;19(6):662‐8. [PUBMED: 15209605] ">Smith 2004</a>). These aminoadamantanes were investigated as oral monotherapy, administered mostly as 100 mg twice a day, and also in combination with interferon‐alpha or ribavirin, or both. The benefits and harms of aminoadamantanes compared with placebo in patients with chronic hepatitis C virus infection have been explored in a meta‐analysis by <a href="./references#CD011132-bbs2-0033" title="DeltenreP , HenrionJ , CanvaV , DharancyS , TexierF , LouvetA , et al. Evaluation of amantadine in chronic hepatitis C: a meta‐analysis. Journal of Hepatology2004;41(3):462‐73. [PUBMED: 15336450] ">Deltenre 2004</a> and in a recent Cochrane systematic review (<a href="./references#CD011132-bbs2-0063" title="LamersMH , BroekmanM , DrenthJPH , GluudC . Aminoadamantanes for chronic hepatitis C. Cochrane Database of Systematic Reviews2014; Vol. (under editorial). [DOI: 10.1002/14651858.CD010125] ">Lamers 2014</a>). </p> </section> <section id="CD011132-sec-0026"> <h3 class="title" id="CD011132-sec-0026">How the intervention might work</h3> <p>Aminoadamantanes have been used for many years to prevent infection with influenza and have been shown to have activity against <i>Flaviviridae, a</i> family of viruses, encompassing hepatitis C virus infection (<a href="./references#CD011132-bbs2-0060" title="KoffWC , ElmJLJr , HalsteadSB . Inhibition of dengue virus replication by amantadine hydrochloride. Antimicrobial Agents and Chemotherapy1980;18(1):125‐9. ">Koff 1980</a>). Known mechanisms of action of aminoadamantanes include inhibition of an early step in viral replication, most likely viral uncoating and interaction with the influenza A viral matrix protein (M2), which is important in virion budding (<a href="./references#CD011132-bbs2-0032" title="DeClercqE . Antiviral drugs: current state of the art. Journal of Clinical Virology2001;22(1):73‐89. ">De Clercq 2001</a>). The aminoadamantane such as amantadine acts similar to ribavirin; ribavirin in monotherapy often improves liver biochemistry (<a href="./references#CD011132-bbs2-0076" title="ReichardO , AnderssonJ , SchvarczR , WeilandO . Ribavirin treatment for chronic hepatitis C. Lancet1991;337(8749):1058‐61. ">Reichard 1991</a>; <a href="./references#CD011132-bbs2-0077" title="ReichardO , YunZB , SonnerborgA , WeilandO . Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C. Journal of Medical Virology1993;41(2):99‐102. ">Reichard 1993</a>), but seems to have no major effect in the course of hepatitis C virus infection on its own (<a href="./references#CD011132-bbs2-0022" title="BrokJ , GluudLL , GluudC . Ribavirin monotherapy for chronic hepatitis C. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD005527.pub2] ">Brok 2009</a>). However, it is unclear whether aminoadamantanes may reduce the hepatitis C virus viral load or improve liver biochemistry (<a href="./references#CD011132-bbs2-0063" title="LamersMH , BroekmanM , DrenthJPH , GluudC . Aminoadamantanes for chronic hepatitis C. Cochrane Database of Systematic Reviews2014; Vol. (under editorial). [DOI: 10.1002/14651858.CD010125] ">Lamers 2014</a>). </p> </section> <section id="CD011132-sec-0027"> <h3 class="title" id="CD011132-sec-0027">Why it is important to do this review</h3> <p>The combination therapy of peg interferon‐alpha and ribavirin yields sustained virological response in approximately 40% to 80% of treated patients (<a href="./references#CD011132-bbs2-0087" title="SiminM , BrokJ , StimacD , GluudC , GluudLL . Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C. Alimentary Pharmacology &amp; Therapeutics2007;25(10):1153‐62. ">Simin 2007</a>; <a href="./references#CD011132-bbs2-0018" title="AwadT , ThorlundK , HauserG , StimacD , MabroukM , GluudC . Peginterferon alpha‐2a is associated with higher sustained virological response than peginterferon alfa‐2b in chronic hepatitis C: systematic review of randomized trials. Hepatology2010;51(4):1176‐84. ">Awad 2010</a>). This indicates an unmet need for drugs in order to reach higher proportions of sustained virological response. With the new direct antiviral agents, higher proportions can be achieved (<a href="./references#CD011132-bbs2-0019" title="BaconBR , GordonSC , LawitzE , MarcellinP , VierlingJM , ZeuzemS , et al. Boceprevir for previously treated chronic HCV genotype 1 infection. New England Journal of Medicine2011;364(13):1207‐17. [PUBMED: 21449784] ">Bacon 2011</a>; <a href="./references#CD011132-bbs2-0053" title="JacobsonIM , McHutchisonJG , DusheikoG , DiBisceglieAM , ReddyKR , BzowejNH , et al. Telaprevir for previously untreated chronic hepatitis C virus infection. New England Journal of Medicine2011;364(25):2405‐16. [PUBMED: 21696307] ">Jacobson 2011</a>; <a href="./references#CD011132-bbs2-0074" title="PoordadF , McConeJJr , BaconBR , BrunoS , MannsMP , SulkowskiMS , et al. Boceprevir for untreated chronic HCV genotype 1 infection. New England Journal of Medicine2011;364(13):1195‐206. [PUBMED: 21449783] ">Poordad 2011</a>; <a href="./references#CD011132-bbs2-0086" title="ShermanKE , FlammSL , AfdhalNH , NelsonDR , SulkowskiMS , EversonGT , et al. Response‐guided telaprevir combination treatment for hepatitis C virus infection. New England Journal of Medicine2011;365(11):1014‐24. [PUBMED: 21916639] ">Sherman 2011</a>; <a href="./references#CD011132-bbs2-0104" title="ZeuzemS , AndreoneP , PolS , LawitzE , DiagoM , RobertsS , et al. Telaprevir for retreatment of HCV infection. New England Journal of Medicine2011;364(25):2417‐28. [PUBMED: 21696308] ">Zeuzem 2011</a>). Several studies have been published regarding the effect of aminoadamantanes. Our systematic review is aimed at assessing the benefits and harms of aminoadamantanes versus other antiviral drugs. This systematic review may have practical implications on the way patients with chronic hepatitis C virus should be treated. </p> <p>The benefits and harms of aminoadamantanes compared with placebo and other antiviral drugs in patients with chronic hepatitis C virus infection have been explored earlier in a meta‐analysis by <a href="./references#CD011132-bbs2-0033" title="DeltenreP , HenrionJ , CanvaV , DharancyS , TexierF , LouvetA , et al. Evaluation of amantadine in chronic hepatitis C: a meta‐analysis. Journal of Hepatology2004;41(3):462‐73. [PUBMED: 15336450] ">Deltenre 2004</a>. A recent Cochrane systematic review compared aminoadamantanes with placebo for chronic hepatitis C (<a href="./references#CD011132-bbs2-0063" title="LamersMH , BroekmanM , DrenthJPH , GluudC . Aminoadamantanes for chronic hepatitis C. Cochrane Database of Systematic Reviews2014; Vol. (under editorial). [DOI: 10.1002/14651858.CD010125] ">Lamers 2014</a>). We found no significant effect of amantadine when compared with placebo or no intervention on sustained virological response or clinical outcomes (<a href="./references#CD011132-bbs2-0063" title="LamersMH , BroekmanM , DrenthJPH , GluudC . Aminoadamantanes for chronic hepatitis C. Cochrane Database of Systematic Reviews2014; Vol. (under editorial). [DOI: 10.1002/14651858.CD010125] ">Lamers 2014</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011132-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011132-sec-0028"></div> <p>To explore the beneficial and harmful effects of aminoadamantanes versus other antiviral drugs for patients with chronic hepatitis C virus infection in a systematic review with meta‐analysis and trial sequential analysis of randomised clinical trials. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011132-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011132-sec-0029"></div> <section id="CD011132-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011132-sec-0031"> <h4 class="title">Types of studies</h4> <p>Randomised clinical trials assessing aminoadamantanes compared with other antiviral drugs in participants with chronic hepatitis C virus infection irrespective of duration of treatment, language, publication type and status, and blinding. Quasi‐randomised studies or other observational studies captured during the search process were excluded for the report of benefit but were reported in a narrative way for the data on harm from such studies. </p> </section> <section id="CD011132-sec-0032"> <h4 class="title">Types of participants</h4> <p>We included participants with chronic hepatitis C virus. The diagnosis was based on the presence of serum hepatitis C virus RNA (HCV RNA) plus elevated transaminases for more than six months, or chronic hepatitis documented on liver biopsy. We also included participants diagnosed with ’non‐A, non‐B’ chronic hepatitis as some trials may have been conducted before HCV RNA analyses were widely available. </p> <p>Based on the existence of, and response to previous antiviral treatment, we classified the included participants as naive (not previously treated with antivirals), relapsers (participants with a transient serological viral response to previous treatment with antivirals), or non‐responders (patients without serological viral response to previous treatment with antivirals). </p> <p>We excluded participants who had undergone liver transplantation.</p> </section> <section id="CD011132-sec-0033"> <h4 class="title">Types of interventions</h4> <p>Aminoadamantanes versus other antiviral drugs.</p> <p>Co‐interventions were allowed if administered equally to the intervention groups being compared. </p> </section> <section id="CD011132-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD011132-sec-0035"> <h5 class="title">Primary outcomes</h5> <p>1. All‐cause mortality or liver‐related morbidity as a composite outcome: number of patients who died or who developed, for example, cirrhosis, ascites, hepatic encephalopathy, or hepatocellular carcinoma.<br/> 2. Adverse events: number of patients with either serious adverse events or treatment discontinuation due to any adverse event. Serious adverse events are defined according to the International Conference on Harmonisation (ICH) Guidelines for Good Clinical Practice as "any untoward medical occurrence that at any dose resulted in death, was life‐threatening, required inpatient hospitalisation or prolongation of existing hospitalisation, or resulted in persistent or significant disability or incapacity, or was a congenital anomaly/birth defect, or any medical event that might have jeopardised the patient, or required intervention to prevent it" (<a href="./references#CD011132-bbs2-0052" title="International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR &amp; ICH Guidelines. Vol. 1, Pennsylvania, USA: Barnett International/PAREXEL, 1997. ">ICH‐GCP 1997</a>). All other adverse events (that is, any medical occurrence not necessarily having a causal relationship with the treatment but that did, however, cause a dose reduction or discontinuation of the treatment) were considered as being non‐serious (<a href="./references#CD011132-bbs2-0052" title="International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR &amp; ICH Guidelines. Vol. 1, Pennsylvania, USA: Barnett International/PAREXEL, 1997. ">ICH‐GCP 1997</a>).<br/> 3. Quality of life (as reported in the trials). </p> </section> <section id="CD011132-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p>1. Failure of serum (or plasma) sustained virological response: number of patients with detectable HCV RNA at least six months after treatment.<br/> 2. Failure of end‐of treatment virological response: number of patients with detectable HCV RNA at the end of treatment.<br/> 3. Failure in histological response: number of patients without improvement of histology (inflammation score (grading) or fibrosis score (staging) as defined by the individual trials).<br/> 4. Number of participants without normalisation of alanine aminotransferase (ALT) or aspartate transaminase (AST) serum levels or both (defined by the individual trials) at end of treatment and end of follow‐up. </p> </section> </section> </section> <section id="CD011132-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011132-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Hepato‐Biliary Group Controlled Trials Register (1996 to December 2013) (<a href="./references#CD011132-bbs2-0044" title="GluudC , NikolovaD , KlingenbergSL , AlexakisN , Als‐NielsenB , ColliA , et al. Cochrane Hepato‐Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2014, Issue 1. Art. No.: LIVER. ">Gluud 2014</a>), the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 11 of 12, 2013), MEDLINE (1946 to December 2013), EMBASE (1974 to December 2013), and Science Citation Index EXPANDED (1900 to December 2013) (<a href="./references#CD011132-bbs2-0080" title="RoyleP , MilneR . Literature searching for randomised controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care2003;19(4):591‐603. ">Royle 2003</a>). We also searched the WHO International Clinical Trials Registry Platform (<a href="http://www.who.int/ictrp" target="_blank">www.who.int/ictrp</a>), Google Scholar, and Eudrapharm. We have given the search strategies in <a href="./appendices#CD011132-sec-0091">Appendix 1</a> with the time spans of the searches. </p> </section> <section id="CD011132-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We identified further trials by reading the reference lists of the identified studies. We checked review articles and meta‐analyses in order to find randomised trials not identified by the electronic searches. We searched for abstracts from various gastrointestinal meetings. We wrote to the principal authors of the identified randomised trials and to the researchers active in the field to enquire about additional randomised trials they might know of. In order to obtain unpublished trials, we contacted pharmaceutical companies involved in the production and assessment of aminoadamantanes. </p> </section> </section> <section id="CD011132-sec-0040"> <h3 class="title" id="CD011132-sec-0040">Data collection and analysis</h3> <section id="CD011132-sec-0041"> <h4 class="title">Selection of studies</h4> <p>Two review authors (ML, MB) independently inspected each reference identified by the searches and applied the inclusion criteria. For possible relevant publications, or in cases of disagreement between the two review authors, the full article was obtained and inspected independently by the two authors. If the two review authors still disagreed, a third review author (CG) was consulted. </p> </section> <section id="CD011132-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (ML, MB) independently extracted data. In case of disagreement between the two review authors, a third review author (CG) arbitrated. The data extraction was discussed, decisions documented, and, where necessary, we contacted trial authors for clarification. Trials were identified by the name of the first author and year in which the study was published in full and ordered chronologically. </p> <p>The following data were extracted, checked, and recorded.</p> <p> <ul id="CD011132-list-0001"> <li> <p>Characteristics of trials: date, location and setting; publication status; sponsor (specified, known or unknown); duration of follow‐up; bias‐domains; sample size calculation. </p> </li> <li> <p>Characteristics of participants: number of participants in each group; age; sex; ethnicity; weight or body mass index; viral load at the beginning of treatment; degree of fibrosis at the beginning of treatment. </p> </li> <li> <p>Characteristics of interventions: dose and duration of aminoadamantanes and any co‐interventions.</p> </li> <li> <p>Characteristics of outcome measures: whenever possible, the number of events previously listed under 'outcome measures' were recorded in each group of the trial; information about harms were extracted in observational studies. </p> </li> </ul> </p> </section> <section id="CD011132-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>According to empirical evidence (<a href="./references#CD011132-bbs2-0083" title="SchultzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273:408‐12. ">Schultz 1995</a>; <a href="./references#CD011132-bbs2-0071" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet1998;352:609‐13. ">Moher 1998</a>; <a href="./references#CD011132-bbs2-0059" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomised trials in meta‐analyses. Annals of Internal Medicine2001;135:982‐9. ">Kjaergard 2001</a>; <a href="./references#CD011132-bbs2-0103" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ (Clinical Research Ed.)2008;336(7644):601‐5. ">Wood 2008</a>; <a href="./references#CD011132-bbs2-0069" title="LundhA , SismondoS , LexchinJ , BusuiocOA , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2; PUBMED: 23235689] ">Lundh 2012</a>; <a href="./references#CD011132-bbs2-0081" title="SavovićJ , JonesH , AltmanD , HarrisR , JuniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta‐epidemiological studies. Health Technology Assessment (Winchester, England)2012;16(35):1‐82. [PUBMED: 22989478] ">Savović 2012</a>; <a href="./references#CD011132-bbs2-0082" title="SavovićJ , JonesHE , AltmanDG , HarrisRJ , JuniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429‐38. [PUBMED: 22945832] ">Savović 2012a</a>), risk of bias in a trial can be assessed using 'Risk of bias' domains. We have used the following domains with definitions to assess the risk of bias of the trials included in the review. </p> <section id="CD011132-sec-0044"> <h5 class="title"><i>Allocation sequence generation</i> </h5> <p> <ul id="CD011132-list-0002"> <li> <p>Low risk of bias: sequence generation was achieved using computer random number generation or a random number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice are adequate if performed by an independent person not otherwise involved in the trial. </p> </li> <li> <p>Uncertain risk of bias: the method of sequence generation was not specified.</p> </li> <li> <p>High risk of bias: the sequence generation method was not random.</p> </li> </ul> </p> </section> <section id="CD011132-sec-0045"> <h5 class="title"><i>Allocation concealment</i> </h5> <p> <ul id="CD011132-list-0003"> <li> <p>Low risk of bias: the participant allocations could not have been foreseen in advance of, or during, enrolment. Allocation was controlled by a central and independent randomisation unit. The allocation sequence was unknown to the investigators (for example, if the allocation sequence was hidden in sequentially numbered, opaque, and sealed envelopes). </p> </li> <li> <p>Uncertain risk of bias: the method used to conceal the allocation was not described so that intervention allocations may have been foreseen in advance of, or during, enrolment. </p> </li> <li> <p>High risk of bias: the allocation sequence was likely to be known to the investigators who assigned the participants. </p> </li> </ul> </p> </section> <section id="CD011132-sec-0046"> <h5 class="title"><i>Blinding of participants, personnel, and outcome assessors</i> </h5> <p> <ul id="CD011132-list-0004"> <li> <p>Low risk of bias: blinding was performed adequately, or the assessment of outcomes was not likely to be influenced by lack of blinding. </p> </li> <li> <p>Uncertain risk of bias: there was insufficient information to assess whether blinding was likely to induce bias on the results. </p> </li> <li> <p>High risk of bias: no blinding or incomplete blinding, and the assessment of outcomes was likely to be influenced by lack of blinding. </p> </li> </ul> </p> </section> <section id="CD011132-sec-0047"> <h5 class="title"><i>Incomplete outcome data</i> </h5> <p> <ul id="CD011132-list-0005"> <li> <p>Low risk of bias: missing data were unlikely to make treatment effects depart from plausible values. Sufficient methods, such as multiple imputation, have been employed to handle missing data. </p> </li> <li> <p>Uncertain risk of bias: there was insufficient information to assess whether missing data in combination with the method used to handle missing data were likely to induce bias on the results. </p> </li> <li> <p>High risk of bias: the results were likely to be biased due to missing data.</p> </li> </ul> </p> </section> <section id="CD011132-sec-0048"> <h5 class="title"><i>Selective outcome reporting</i> </h5> <p> <ul id="CD011132-list-0006"> <li> <p>Low risk of bias: all outcomes were pre‐defined and reported, or all clinically relevant and reasonably expected outcomes were reported. </p> </li> <li> <p>Uncertain risk of bias: it is unclear whether all pre‐defined and clinically relevant and reasonably expected outcomes were reported. </p> </li> <li> <p>High risk of bias: one or more clinically relevant and reasonably expected outcomes were not reported, and data on these outcomes were likely to have been recorded. </p> </li> </ul> </p> <p>For a trial to be assessed with low risk of bias in the selective outcome reporting domain, the trial should have been registered either on the <a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a> web site or a similar register, or there should be a protocol, for example published in a paper journal. In the case where the trial was run and published in the years when trial registration was not required, we carefully scrutinised all publications reporting on the trial to identify the trial objectives and outcomes. If usable data on all outcomes specified in the trial objectives were provided in the publication's results section, then the trial can be considered low risk of bias in the 'Selective outcome reporting' domain. </p> </section> <section id="CD011132-sec-0049"> <h5 class="title"><i>For‐profit bias</i> </h5> <p> <ul id="CD011132-list-0007"> <li> <p>Low risk of bias: the trial appeared to be free of industry sponsorship or other kind of for‐profit support that might have result in manipulation of the trial design, conduct, or results of the trial. </p> </li> <li> <p>Uncertain risk of bias: the trial might or might not be free of for‐profit bias as no information on clinical trial support or sponsorship is provided. </p> </li> <li> <p>High risk of bias: the trial was sponsored by industry or had received other kinds of for‐profit support. </p> </li> </ul> </p> <p>All trials were assessed for risk of bias. If the risk of bias in a trial was judged as 'low' in all the above listed domains, then the trial was considered at 'low risk of bias'. If the risk of bias was judged as 'uncertain' or 'high', then the trial was considered at 'high risk of bias'. </p> <p>Reporting bias was handled following the recommendations of The Cochrane Collaboration (<a href="./references#CD011132-bbs2-0049" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Subgroup analyses (see below) and funnel plot asymmetry were assessed (<a href="./references#CD011132-bbs2-0049" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), even though asymmetric funnel plots are not necessarily caused by publication bias and publication bias does not necessarily cause asymmetry in a funnel plot (<a href="./references#CD011132-bbs2-0038" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.)1997;315(7109):629‐34. ">Egger 1997</a>). </p> </section> </section> <section id="CD011132-sec-0050"> <h4 class="title">Measures of treatment effect</h4> <p>The treatment effects in this meta‐analysis are dichotomous or continuous. The dichotomous data were expressed with risk ratio (RR) and 95% confidence intervals (CI). The number needed to treat (NNT) was derived from the risk difference (RD), in case the intervention effect was considered significant and valid. For continuous data, we planned to use the mean difference when outcomes of the trials were measured in the same way. Where appropriate, we would have used the standardised mean difference to combine trials that measured the same outcome but used different methods. </p> </section> <section id="CD011132-sec-0051"> <h4 class="title">Unit of analysis issues</h4> <p>We used the intervention groups of participants in randomised clinical trials as our unit of analysis. Three included trials used a two‐armed parallel group design; the other three trials used a multiple‐armed parallel group design. We present those additional treatment arms in the 'Summary of characteristics of included studies', see <a href="#CD011132-tbl-0002">Table 1</a>. Where the additional treatment arms were not relevant, we did not use these data. </p> <div class="table" id="CD011132-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of characteristics of the included trials</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial duration (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Follow‐up duration (months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Amantadine versus ribavirin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011132-bbs2-0004" title="KhaliliM , DenhamC , PerrilloR . A comparison of combination therapy with interferon and ribavirin vs interferon and amantadine in interferon non‐responders with chronic hepatitis C. Hepatology1999;28(4):169A. KhaliliM , DenhamC , PerrilloR . Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C. American Journal of Gastroenterology2000;95(5):1284‐9. [PUBMED: 10811340] ">Khalili 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011132-bbs2-0006" title="YounossiZM , MullenKD , ZakkoW , BrandtE , HodnickS , BarnesD , et al. Interferon alpha2B‐ribavirin vs. interferon alpha2B‐amantadine combination in chronic hepatitis C; analyses of a randomized, double‐blind trial. Hepatology1999;30(4):372A. YounossiZM , MullenKD , ZakkoW , BrandtE , HodnickS , EasleyK , et al. Interferon alpha2b and ribavirin vs interferon alpha2b and amantadine for chronic hepatitis C (non‐responder): a multi‐center, randomized, double‐blind trial. Hepatology1998;28(4):284A. YounossiZM , MullenKD , ZakkoW , HodnickS , BrandE , BarnesDS , et al. A randomized, double‐blind controlled trial of interferon alpha‐2b and ribavirin vs. interferon alpha‐2b and amantadine for treatment of chronic hepatitis C non‐responder to interferon monotherapy. Journal of Hepatology2001;34(1):128‐33. [PUBMED: 11211889] ">Younossi 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011132-bbs2-0003" title="HerrineSK , BrownRSJr , BernsteinDE , OndovikMS , LentzE , TeH . Peginterferon alpha‐2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha‐2b plus ribavirin: a pilot study of efficacy and safety. Digestive Diseases and Sciences2005;50(4):719‐26. ">Herrine 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011132-bbs2-0005" title="SalmeronJ , DiagoM , AndradeR , PerezR , SolaR , RomeroM , et al. Induction doses of interferon‐alpha‐2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non‐responders to interferon monotherapy: a randomized trial. Journal of Viral Hepatitis2007;14(2):89‐95. ">Salmeron 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Amantadine versus mycophenolate mofetil</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011132-bbs2-0003" title="HerrineSK , BrownRSJr , BernsteinDE , OndovikMS , LentzE , TeH . Peginterferon alpha‐2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha‐2b plus ribavirin: a pilot study of efficacy and safety. Digestive Diseases and Sciences2005;50(4):719‐26. ">Herrine 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Amantadine versus interferon‐alpha</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011132-bbs2-0002" title="BacosiM , RussoF , DínnocenzoS , SantolamazzaM , MiglioresiL , UrsittiA , et al. Amantadine and interferon in the combined treatment of hepatitis C virus in elderly patients. Hepatology Research2002;22(3):231‐9. ">Bacosi 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Amantadine versus interferon‐gamma</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011132-bbs2-0001" title="AbbasZ , RazaS , HamidS , JafriW . Randomized controlled trial of interferon gamma versus amantadine in combination with interferon alpha and ribavirin for hepatitis C genotype 3 non‐responders and relapsers. Journal of the Pakistan Medical Association2012;62:338‐43. ">Abbas 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD011132-sec-0052"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the original investigators to request missing data that we expected to have been measured but were not reported. </p> <p>We performed all analyses according to the intention‐to‐treat method, including all participants irrespective of compliance or follow‐up. </p> <p>Regarding our primary outcomes, we included patients with incomplete or missing data in sensitivity analyses by imputing them according to the following two extreme scenarios (<a href="./references#CD011132-bbs2-0050" title="HollisS , CampbellF . What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ (Clinical Research Ed.)1999;319(7211):670‐4. ">Hollis 1999</a>; <a href="./references#CD011132-bbs2-0044" title="GluudC , NikolovaD , KlingenbergSL , AlexakisN , Als‐NielsenB , ColliA , et al. Cochrane Hepato‐Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2014, Issue 1. Art. No.: LIVER. ">Gluud 2014</a>). </p> <p> <ul id="CD011132-list-0008"> <li> <p>Extreme case analysis favouring the experimental intervention ('best‐worse' case scenario): none of the dropouts/participants lost from the experimental arm, but all of the dropouts/participants lost from the control group experienced the outcome, including all randomised participants in the denominator. </p> </li> <li> <p>Extreme case analysis favouring the control ('worst‐best' case scenario): all dropouts/participants lost from the experimental arm, but none from the control arm experienced the outcome, including all randomised participants in the denominator. </p> </li> </ul> </p> </section> <section id="CD011132-sec-0053"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity using the chi‐squared statistic test of heterogeneity and quantity of heterogeneity by the I<sup>2</sup> measure of inconsistency (<a href="./references#CD011132-bbs2-0049" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). In case of substantial heterogeneity as measured by a chi‐square test P value less than 0.1 or an I<sup>2</sup> measure greater than 70%, we considered not to conduct the meta‐analysis. We assessed sources of clinical, methodological, and statistical heterogeneity in subgroup analyses. </p> </section> <section id="CD011132-sec-0054"> <h4 class="title">Assessment of reporting biases</h4> <p>Described under '<a href="#CD011132-sec-0043">Assessment of risk of bias in included studies</a>'. </p> </section> <section id="CD011132-sec-0055"> <h4 class="title">Data synthesis</h4> <section id="CD011132-sec-0056"> <h5 class="title">Meta‐analysis</h5> <p>For the statistical analyses, we used Review Manager 5.2 (<a href="./references#CD011132-bbs2-0078" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>). We meta‐analysed the data with both a random‐effects model (<a href="./references#CD011132-bbs2-0035" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7(3):177‐88. ">DerSimonian 1986</a>) and a fixed‐effect model (<a href="./references#CD011132-bbs2-0034" title="DeMetsDL . Methods for combining randomised clinical trials: strengths and limitations. Statistics in Medicine1987;6(3):341‐50. ">DeMets 1987</a>) to ensure robustness of the results. In case of statistically significant differences of the results that the two methods produced, we presented the results with both methods. If there were no differences in the results, we presented the results of the fixed‐effect model only (<a href="./references#CD011132-bbs2-0049" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). If there was considerable variation in the results, and particularly if the direction of effect was inconsistent, it may be misleading to quote the average value for the intervention effect; we therefore interpreted the meta‐analyses with utmost care. </p> </section> <section id="CD011132-sec-0057"> <h5 class="title">Trial sequential analysis</h5> <p>We applied trial sequential analysis (<a href="./references#CD011132-bbs2-0029" title="Copenhagen Trial Unit. TSA ‐ Trial Sequential Analysis. ctu.dk/tsa/ 2011 (accessed 19 March 2014). ">CTU 2011</a>; <a href="./references#CD011132-bbs2-0096" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual forTrial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 20 March 2014). ">Thorlund 2011</a>) as cumulative meta‐analyses are at risk of producing random errors due to sparse data and repetitive testing of the accumulating data (<a href="./references#CD011132-bbs2-0021" title="BrokJ , ThorlundK , GluudC , WetterslevJ . Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta‐analyses. Journal of Clinical Epidemiology2008;61(8):763‐9. ">Brok 2008</a>; <a href="./references#CD011132-bbs2-0100" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. ">Wetterslev 2008</a>; <a href="./references#CD011132-bbs2-0022" title="BrokJ , GluudLL , GluudC . Ribavirin monotherapy for chronic hepatitis C. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD005527.pub2] ">Brok 2009</a>). To minimise random errors, we calculated the required information size (i.e., the number of participants needed in a meta‐analysis to detect or reject a certain intervention effect) (<a href="./references#CD011132-bbs2-0100" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. ">Wetterslev 2008</a>). The required information size calculation should also account for the heterogeneity or diversity present in the meta‐analysis (<a href="./references#CD011132-bbs2-0100" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. ">Wetterslev 2008</a>; <a href="./references#CD011132-bbs2-0101" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random effects model meta‐analyses. BMC Medical Research Methodology2009;9:86. ">Wetterslev 2009</a>). In our meta‐analysis, the diversity‐adjusted required information size was based on the event proportion in the control group; assumption of a plausible RR reduction of 20% or the RR reduction observed in the included trials with low risk of bias; a risk of type I error of 5%; a risk of type II error of 20%; and the assumed diversity of the meta‐analysis (<a href="./references#CD011132-bbs2-0101" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random effects model meta‐analyses. BMC Medical Research Methodology2009;9:86. ">Wetterslev 2009</a>). We added the trials according to the year of publication, and if more than one trial was published in a year, trials were added alphabetically according to the last name of the first author. On the basis of the required information size, trial sequential monitoring boundaries were constructed (<a href="http://archie.cochrane.org/sections/documents/view?document=z1311151715122955881340818799728%26format=REVMAN#REF-Lan-1983" target="_blank">Lan 1983</a>; <a href="./references#CD011132-bbs2-0100" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. ">Wetterslev 2008</a>; <a href="./references#CD011132-bbs2-0096" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual forTrial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 20 March 2014). ">Thorlund 2011</a>). These boundaries determine the statistical inference one may draw regarding the cumulative meta‐analysis that has not reached the required information size; if the trial sequential monitoring boundary for benefit or harm is crossed before the required information size is reached, firm evidence may perhaps be established and further trials may turn out to be superfluous. On the other hand, if the boundary is not surpassed, it is most probably necessary to continue doing trials in order to detect or reject a certain intervention effect. This can be determined by assessing if the cumulative Z‐curve crosses the trial sequential boundaries for futility. If futility boundaries are crossed, then further trials may be unnecessary (<a href="./references#CD011132-bbs2-0029" title="Copenhagen Trial Unit. TSA ‐ Trial Sequential Analysis. ctu.dk/tsa/ 2011 (accessed 19 March 2014). ">CTU 2011</a>). </p> <p>We conducted trial sequential analyses using software from The Copenhagen Trial Unit (<a href="./references#CD011132-bbs2-0029" title="Copenhagen Trial Unit. TSA ‐ Trial Sequential Analysis. ctu.dk/tsa/ 2011 (accessed 19 March 2014). ">CTU 2011</a>). </p> </section> </section> <section id="CD011132-sec-0058"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Subgroup analyses were performed to compare the following.</p> <p> <ul id="CD011132-list-0009"> <li> <p>Trials with low risk compared to trials with high risk of bias.</p> </li> <li> <p>Type of patients regarding previous antivirals: naives, relapsers, and non‐responders.</p> </li> <li> <p>Type of patients regarding genotype: genotype 1 compared to genotype non‐1.</p> </li> <li> <p>Type of patients regarding degree of liver disease (inflammation score (grading) or fibrosis score (staging)). </p> </li> <li> <p>Type of patients regarding HIV or hepatitis B co‐infection.</p> </li> <li> <p>Type of patients regarding age: children compared to adults.</p> </li> <li> <p>Intervention: according to the type, dose and duration of aminoadamantanes, and other viral drugs. </p> </li> </ul> </p> <p>Subgroups were compared with test of interaction (<a href="./references#CD011132-bbs2-0015" title="AltmanDG , BlandJM . Interaction revisited: the difference between two estimates. BMJ (Clinical Research Ed.)2003;326(7382):219. ">Altman 2003</a>). </p> </section> <section id="CD011132-sec-0059"> <h4 class="title">Sensitivity analysis</h4> <p>Suitable sensitivity analyses were identified during the review process, e.g., a sensitivity analysis was used when imputing missing data with replacement values. </p> <p>Data analysis in included trials: according to intention‐to‐treat principle as well as 'as treated' (per protocol) analysis. </p> <section id="CD011132-sec-0060"> <h5 class="title">'Summary of findings' table</h5> <p>We used the principles of the GRADE system to assess the quality of the body of evidence associated with all outcomes mentioned in our review and constructed 'Summary of findings' table using the GRADE software (<a href="http://ims.cochrane.org/revman/gradepro" target="_blank">ims.cochrane.org/revman/gradepro</a>). </p> <p>We assessed five factors referring to limitations in the study design and implementation of available studies suggesting high likelihood of bias; indirectness of evidence (population, intervention, control, outcomes); unexplained heterogeneity or inconsistency of results (including problems with subgroup analyses); imprecision of results (wide confidence intervals); and high probability of publication bias. </p> <p>We defined the levels of evidence as:</p> <p> <ul id="CD011132-list-0010"> <li> <p>high‐quality evidence when all bias domains were assessed with low risk of bias and there were consistent findings that were generalisable to most of the population of interest; there were sufficient data, with narrow confidence intervals; there were no known or suspected reporting biases; in such a case, "further research is very unlikely to change our confidence in the estimate of effect"; </p> </li> <li> <p>moderate‐quality evidence when "further research is likely to have an important impact on our confidence in the estimate of effect, and may change the estimate"; </p> </li> <li> <p>low‐quality evidence when the following statement applies: "further research is very likely to have an important impact on our confidence in the estimate of effect, and is likely to change the estimate"; </p> </li> <li> <p>very low‐quality evidence when the following statement applies: "we are very uncertain about the estimate". </p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011132-sec-0061" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011132-sec-0061"></div> <section id="CD011132-sec-0062"> <h3 class="title">Description of studies</h3> <p>See: <a href="./references#CD011132-sec-0099" title="">Characteristics of included studies</a>; <a href="./references#CD011132-sec-0100" title="">Characteristics of excluded studies</a>. </p> <section id="CD011132-sec-0063"> <h4 class="title">Results of the search  </h4> <p>We identified 639 references through the electronic searches. After filtering for duplicates, 290 publications remained. Of the remaining 290 publications, 281 were excluded after screening the title and abstract, among others because they were reviews or because they did not describe a randomised clinical trial investigating the effect of aminoadamantanes in patients with chronic hepatitis C virus. The remaining nine references described six unique randomised clinical trials (<a href="#CD011132-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD011132-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram." data-id="CD011132-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram.</p> </div> </div> </div> <p>Two of these six included trials were published in more than one publication (<a href="./references#CD011132-bbs2-0004" title="KhaliliM , DenhamC , PerrilloR . A comparison of combination therapy with interferon and ribavirin vs interferon and amantadine in interferon non‐responders with chronic hepatitis C. Hepatology1999;28(4):169A. KhaliliM , DenhamC , PerrilloR . Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C. American Journal of Gastroenterology2000;95(5):1284‐9. [PUBMED: 10811340] ">Khalili 2000</a>; <a href="./references#CD011132-bbs2-0006" title="YounossiZM , MullenKD , ZakkoW , BrandtE , HodnickS , BarnesD , et al. Interferon alpha2B‐ribavirin vs. interferon alpha2B‐amantadine combination in chronic hepatitis C; analyses of a randomized, double‐blind trial. Hepatology1999;30(4):372A. YounossiZM , MullenKD , ZakkoW , BrandtE , HodnickS , EasleyK , et al. Interferon alpha2b and ribavirin vs interferon alpha2b and amantadine for chronic hepatitis C (non‐responder): a multi‐center, randomized, double‐blind trial. Hepatology1998;28(4):284A. YounossiZM , MullenKD , ZakkoW , HodnickS , BrandE , BarnesDS , et al. A randomized, double‐blind controlled trial of interferon alpha‐2b and ribavirin vs. interferon alpha‐2b and amantadine for treatment of chronic hepatitis C non‐responder to interferon monotherapy. Journal of Hepatology2001;34(1):128‐33. [PUBMED: 11211889] ">Younossi 2001</a>). All six trials were published in full paper articles (<a href="./references#CD011132-bbs2-0004" title="KhaliliM , DenhamC , PerrilloR . A comparison of combination therapy with interferon and ribavirin vs interferon and amantadine in interferon non‐responders with chronic hepatitis C. Hepatology1999;28(4):169A. KhaliliM , DenhamC , PerrilloR . Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C. American Journal of Gastroenterology2000;95(5):1284‐9. [PUBMED: 10811340] ">Khalili 2000</a>; <a href="./references#CD011132-bbs2-0006" title="YounossiZM , MullenKD , ZakkoW , BrandtE , HodnickS , BarnesD , et al. Interferon alpha2B‐ribavirin vs. interferon alpha2B‐amantadine combination in chronic hepatitis C; analyses of a randomized, double‐blind trial. Hepatology1999;30(4):372A. YounossiZM , MullenKD , ZakkoW , BrandtE , HodnickS , EasleyK , et al. Interferon alpha2b and ribavirin vs interferon alpha2b and amantadine for chronic hepatitis C (non‐responder): a multi‐center, randomized, double‐blind trial. Hepatology1998;28(4):284A. YounossiZM , MullenKD , ZakkoW , HodnickS , BrandE , BarnesDS , et al. A randomized, double‐blind controlled trial of interferon alpha‐2b and ribavirin vs. interferon alpha‐2b and amantadine for treatment of chronic hepatitis C non‐responder to interferon monotherapy. Journal of Hepatology2001;34(1):128‐33. [PUBMED: 11211889] ">Younossi 2001</a>; <a href="./references#CD011132-bbs2-0002" title="BacosiM , RussoF , DínnocenzoS , SantolamazzaM , MiglioresiL , UrsittiA , et al. Amantadine and interferon in the combined treatment of hepatitis C virus in elderly patients. Hepatology Research2002;22(3):231‐9. ">Bacosi 2002</a>; <a href="./references#CD011132-bbs2-0003" title="HerrineSK , BrownRSJr , BernsteinDE , OndovikMS , LentzE , TeH . Peginterferon alpha‐2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha‐2b plus ribavirin: a pilot study of efficacy and safety. Digestive Diseases and Sciences2005;50(4):719‐26. ">Herrine 2005</a>; <a href="./references#CD011132-bbs2-0005" title="SalmeronJ , DiagoM , AndradeR , PerezR , SolaR , RomeroM , et al. Induction doses of interferon‐alpha‐2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non‐responders to interferon monotherapy: a randomized trial. Journal of Viral Hepatitis2007;14(2):89‐95. ">Salmeron 2007</a>; <a href="./references#CD011132-bbs2-0001" title="AbbasZ , RazaS , HamidS , JafriW . Randomized controlled trial of interferon gamma versus amantadine in combination with interferon alpha and ribavirin for hepatitis C genotype 3 non‐responders and relapsers. Journal of the Pakistan Medical Association2012;62:338‐43. ">Abbas 2012</a>). </p> <p>When necessary, the primary or last authors were contacted for further information and data relating to the trials. </p> <p>We did not identify any registered ongoing or planned trials when we searched the WHO International Clinical Trials Registry Platform (www.who.int/ictrp), Google Scholar, and Eudrapharm. </p> </section> <section id="CD011132-sec-0064"> <h4 class="title">Included studies  </h4> <p>We included six trials in total. Three trials were conducted in the USA (<a href="./references#CD011132-bbs2-0004" title="KhaliliM , DenhamC , PerrilloR . A comparison of combination therapy with interferon and ribavirin vs interferon and amantadine in interferon non‐responders with chronic hepatitis C. Hepatology1999;28(4):169A. KhaliliM , DenhamC , PerrilloR . Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C. American Journal of Gastroenterology2000;95(5):1284‐9. [PUBMED: 10811340] ">Khalili 2000</a>; <a href="./references#CD011132-bbs2-0006" title="YounossiZM , MullenKD , ZakkoW , BrandtE , HodnickS , BarnesD , et al. Interferon alpha2B‐ribavirin vs. interferon alpha2B‐amantadine combination in chronic hepatitis C; analyses of a randomized, double‐blind trial. Hepatology1999;30(4):372A. YounossiZM , MullenKD , ZakkoW , BrandtE , HodnickS , EasleyK , et al. Interferon alpha2b and ribavirin vs interferon alpha2b and amantadine for chronic hepatitis C (non‐responder): a multi‐center, randomized, double‐blind trial. Hepatology1998;28(4):284A. YounossiZM , MullenKD , ZakkoW , HodnickS , BrandE , BarnesDS , et al. A randomized, double‐blind controlled trial of interferon alpha‐2b and ribavirin vs. interferon alpha‐2b and amantadine for treatment of chronic hepatitis C non‐responder to interferon monotherapy. Journal of Hepatology2001;34(1):128‐33. [PUBMED: 11211889] ">Younossi 2001</a>; <a href="./references#CD011132-bbs2-0003" title="HerrineSK , BrownRSJr , BernsteinDE , OndovikMS , LentzE , TeH . Peginterferon alpha‐2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha‐2b plus ribavirin: a pilot study of efficacy and safety. Digestive Diseases and Sciences2005;50(4):719‐26. ">Herrine 2005</a>). The other three trials were conducted each in different countries: Italy (<a href="./references#CD011132-bbs2-0002" title="BacosiM , RussoF , DínnocenzoS , SantolamazzaM , MiglioresiL , UrsittiA , et al. Amantadine and interferon in the combined treatment of hepatitis C virus in elderly patients. Hepatology Research2002;22(3):231‐9. ">Bacosi 2002</a>), Pakistan (<a href="./references#CD011132-bbs2-0001" title="AbbasZ , RazaS , HamidS , JafriW . Randomized controlled trial of interferon gamma versus amantadine in combination with interferon alpha and ribavirin for hepatitis C genotype 3 non‐responders and relapsers. Journal of the Pakistan Medical Association2012;62:338‐43. ">Abbas 2012</a>), and Spain (<a href="./references#CD011132-bbs2-0005" title="SalmeronJ , DiagoM , AndradeR , PerezR , SolaR , RomeroM , et al. Induction doses of interferon‐alpha‐2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non‐responders to interferon monotherapy: a randomized trial. Journal of Viral Hepatitis2007;14(2):89‐95. ">Salmeron 2007</a>) (see <a href="./references#CD011132-sec-0099" title="">Characteristics of included studies</a>). </p> <p>The included trials were published from 2000 (<a href="./references#CD011132-bbs2-0004" title="KhaliliM , DenhamC , PerrilloR . A comparison of combination therapy with interferon and ribavirin vs interferon and amantadine in interferon non‐responders with chronic hepatitis C. Hepatology1999;28(4):169A. KhaliliM , DenhamC , PerrilloR . Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C. American Journal of Gastroenterology2000;95(5):1284‐9. [PUBMED: 10811340] ">Khalili 2000</a>) to 2012 (<a href="./references#CD011132-bbs2-0001" title="AbbasZ , RazaS , HamidS , JafriW . Randomized controlled trial of interferon gamma versus amantadine in combination with interferon alpha and ribavirin for hepatitis C genotype 3 non‐responders and relapsers. Journal of the Pakistan Medical Association2012;62:338‐43. ">Abbas 2012</a>). Three trials had a parallel group design with two intervention groups (<a href="./references#CD011132-bbs2-0004" title="KhaliliM , DenhamC , PerrilloR . A comparison of combination therapy with interferon and ribavirin vs interferon and amantadine in interferon non‐responders with chronic hepatitis C. Hepatology1999;28(4):169A. KhaliliM , DenhamC , PerrilloR . Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C. American Journal of Gastroenterology2000;95(5):1284‐9. [PUBMED: 10811340] ">Khalili 2000</a>; <a href="./references#CD011132-bbs2-0006" title="YounossiZM , MullenKD , ZakkoW , BrandtE , HodnickS , BarnesD , et al. Interferon alpha2B‐ribavirin vs. interferon alpha2B‐amantadine combination in chronic hepatitis C; analyses of a randomized, double‐blind trial. Hepatology1999;30(4):372A. YounossiZM , MullenKD , ZakkoW , BrandtE , HodnickS , EasleyK , et al. Interferon alpha2b and ribavirin vs interferon alpha2b and amantadine for chronic hepatitis C (non‐responder): a multi‐center, randomized, double‐blind trial. Hepatology1998;28(4):284A. YounossiZM , MullenKD , ZakkoW , HodnickS , BrandE , BarnesDS , et al. A randomized, double‐blind controlled trial of interferon alpha‐2b and ribavirin vs. interferon alpha‐2b and amantadine for treatment of chronic hepatitis C non‐responder to interferon monotherapy. Journal of Hepatology2001;34(1):128‐33. [PUBMED: 11211889] ">Younossi 2001</a>; <a href="./references#CD011132-bbs2-0001" title="AbbasZ , RazaS , HamidS , JafriW . Randomized controlled trial of interferon gamma versus amantadine in combination with interferon alpha and ribavirin for hepatitis C genotype 3 non‐responders and relapsers. Journal of the Pakistan Medical Association2012;62:338‐43. ">Abbas 2012</a>). One trial included three intervention groups (<a href="./references#CD011132-bbs2-0002" title="BacosiM , RussoF , DínnocenzoS , SantolamazzaM , MiglioresiL , UrsittiA , et al. Amantadine and interferon in the combined treatment of hepatitis C virus in elderly patients. Hepatology Research2002;22(3):231‐9. ">Bacosi 2002</a>) and two trials included four intervention groups (<a href="./references#CD011132-bbs2-0003" title="HerrineSK , BrownRSJr , BernsteinDE , OndovikMS , LentzE , TeH . Peginterferon alpha‐2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha‐2b plus ribavirin: a pilot study of efficacy and safety. Digestive Diseases and Sciences2005;50(4):719‐26. ">Herrine 2005</a>; <a href="./references#CD011132-bbs2-0005" title="SalmeronJ , DiagoM , AndradeR , PerezR , SolaR , RomeroM , et al. Induction doses of interferon‐alpha‐2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non‐responders to interferon monotherapy: a randomized trial. Journal of Viral Hepatitis2007;14(2):89‐95. ">Salmeron 2007</a>). </p> <p>The six randomised clinical trials randomised 581 patients with chronic hepatitis C virus to amantadine versus control. The control arms consisted of ribavirin, mycophenolate mofetil, interferon‐alpha, or interferon‐gamma. </p> <p>Three trials compared amantadine plus interferon‐alpha versus ribavirin plus interferon‐alpha (<a href="./references#CD011132-bbs2-0004" title="KhaliliM , DenhamC , PerrilloR . A comparison of combination therapy with interferon and ribavirin vs interferon and amantadine in interferon non‐responders with chronic hepatitis C. Hepatology1999;28(4):169A. KhaliliM , DenhamC , PerrilloR . Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C. American Journal of Gastroenterology2000;95(5):1284‐9. [PUBMED: 10811340] ">Khalili 2000</a>; <a href="./references#CD011132-bbs2-0006" title="YounossiZM , MullenKD , ZakkoW , BrandtE , HodnickS , BarnesD , et al. Interferon alpha2B‐ribavirin vs. interferon alpha2B‐amantadine combination in chronic hepatitis C; analyses of a randomized, double‐blind trial. Hepatology1999;30(4):372A. YounossiZM , MullenKD , ZakkoW , BrandtE , HodnickS , EasleyK , et al. Interferon alpha2b and ribavirin vs interferon alpha2b and amantadine for chronic hepatitis C (non‐responder): a multi‐center, randomized, double‐blind trial. Hepatology1998;28(4):284A. YounossiZM , MullenKD , ZakkoW , HodnickS , BrandE , BarnesDS , et al. A randomized, double‐blind controlled trial of interferon alpha‐2b and ribavirin vs. interferon alpha‐2b and amantadine for treatment of chronic hepatitis C non‐responder to interferon monotherapy. Journal of Hepatology2001;34(1):128‐33. [PUBMED: 11211889] ">Younossi 2001</a>; <a href="./references#CD011132-bbs2-0005" title="SalmeronJ , DiagoM , AndradeR , PerezR , SolaR , RomeroM , et al. Induction doses of interferon‐alpha‐2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non‐responders to interferon monotherapy: a randomized trial. Journal of Viral Hepatitis2007;14(2):89‐95. ">Salmeron 2007</a>). One trial compared amantadine monotherapy with interferon‐alpha without additional antiviral drugs (<a href="./references#CD011132-bbs2-0002" title="BacosiM , RussoF , DínnocenzoS , SantolamazzaM , MiglioresiL , UrsittiA , et al. Amantadine and interferon in the combined treatment of hepatitis C virus in elderly patients. Hepatology Research2002;22(3):231‐9. ">Bacosi 2002</a>). One trial reported on amantadine plus interferon‐alpha plus ribavirin versus interferon‐gamma plus interferon‐alpha plus ribavirin (<a href="./references#CD011132-bbs2-0001" title="AbbasZ , RazaS , HamidS , JafriW . Randomized controlled trial of interferon gamma versus amantadine in combination with interferon alpha and ribavirin for hepatitis C genotype 3 non‐responders and relapsers. Journal of the Pakistan Medical Association2012;62:338‐43. ">Abbas 2012</a>). Another trial compared amantadine plus peg interferon‐alpha versus mycophenolate mofetil plus peg interferon‐alpha (<a href="./references#CD011132-bbs2-0003" title="HerrineSK , BrownRSJr , BernsteinDE , OndovikMS , LentzE , TeH . Peginterferon alpha‐2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha‐2b plus ribavirin: a pilot study of efficacy and safety. Digestive Diseases and Sciences2005;50(4):719‐26. ">Herrine 2005</a>). This trial also reported on the comparison of amantadine plus peg interferon‐alpha versus ribavirin plus peg interferon‐alpha (<a href="./references#CD011132-bbs2-0003" title="HerrineSK , BrownRSJr , BernsteinDE , OndovikMS , LentzE , TeH . Peginterferon alpha‐2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha‐2b plus ribavirin: a pilot study of efficacy and safety. Digestive Diseases and Sciences2005;50(4):719‐26. ">Herrine 2005</a>). </p> <p>Amantadine dose was the same in each trial, 200 mg daily. The treatment duration of the trials varied from six to 12 months. A six‐month post‐treatment duration of follow‐up was used in all trials, except for one trial which applied 12 months of post‐treatment follow‐up (<a href="./references#CD011132-bbs2-0002" title="BacosiM , RussoF , DínnocenzoS , SantolamazzaM , MiglioresiL , UrsittiA , et al. Amantadine and interferon in the combined treatment of hepatitis C virus in elderly patients. Hepatology Research2002;22(3):231‐9. ">Bacosi 2002</a>). The details are displayed in <a href="#CD011132-tbl-0002">Table 1</a>. </p> <p>All publications reported the sex of the participants; more than 67% were men. All trials included adult patients. None of the trials included patients co‐infected with HIV or hepatitis B virus infection. </p> </section> <section id="CD011132-sec-0065"> <h4 class="title">Excluded studies  </h4> <p>The eight excluded studies are listed under '<a href="./references#CD011132-sec-0100" title="">Characteristics of excluded studies</a>', and the reasons for exclusion are given there. </p> </section> </section> <section id="CD011132-sec-0066"> <h3 class="title">Risk of bias in included studies</h3> <p>Risk of bias was assessed according to six domains: allocation sequence generation; allocation concealment; blinding of participants, personnel, and outcome assessors; handling of incomplete outcome data; selective outcome reporting; and for‐profit bias. All included trials were considered to have high risk of bias. Our statistical analysis are, therefore, based on trials with a high risk of bias. For details of the judgements made for the individual trials, please see <a href="#CD011132-fig-0002">Figure 2</a> and <a href="#CD011132-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD011132-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011132-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD011132-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011132-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011132-sec-0067"> <h4 class="title">Allocation (selection bias)  </h4> <p>The generation of the allocation sequence was adequately described in only one trial (<a href="./references#CD011132-bbs2-0006" title="YounossiZM , MullenKD , ZakkoW , BrandtE , HodnickS , BarnesD , et al. Interferon alpha2B‐ribavirin vs. interferon alpha2B‐amantadine combination in chronic hepatitis C; analyses of a randomized, double‐blind trial. Hepatology1999;30(4):372A. YounossiZM , MullenKD , ZakkoW , BrandtE , HodnickS , EasleyK , et al. Interferon alpha2b and ribavirin vs interferon alpha2b and amantadine for chronic hepatitis C (non‐responder): a multi‐center, randomized, double‐blind trial. Hepatology1998;28(4):284A. YounossiZM , MullenKD , ZakkoW , HodnickS , BrandE , BarnesDS , et al. A randomized, double‐blind controlled trial of interferon alpha‐2b and ribavirin vs. interferon alpha‐2b and amantadine for treatment of chronic hepatitis C non‐responder to interferon monotherapy. Journal of Hepatology2001;34(1):128‐33. [PUBMED: 11211889] ">Younossi 2001</a>). The remaining five trials were described as randomised, but the method or performing random sequence generation was not described or the randomisation was done by the principle investigator (<a href="./references#CD011132-sec-0099" title="">Characteristics of included studies</a>). </p> <p>The method used to conceal allocation was adequately described in three trials (<a href="./references#CD011132-bbs2-0006" title="YounossiZM , MullenKD , ZakkoW , BrandtE , HodnickS , BarnesD , et al. Interferon alpha2B‐ribavirin vs. interferon alpha2B‐amantadine combination in chronic hepatitis C; analyses of a randomized, double‐blind trial. Hepatology1999;30(4):372A. YounossiZM , MullenKD , ZakkoW , BrandtE , HodnickS , EasleyK , et al. Interferon alpha2b and ribavirin vs interferon alpha2b and amantadine for chronic hepatitis C (non‐responder): a multi‐center, randomized, double‐blind trial. Hepatology1998;28(4):284A. YounossiZM , MullenKD , ZakkoW , HodnickS , BrandE , BarnesDS , et al. A randomized, double‐blind controlled trial of interferon alpha‐2b and ribavirin vs. interferon alpha‐2b and amantadine for treatment of chronic hepatitis C non‐responder to interferon monotherapy. Journal of Hepatology2001;34(1):128‐33. [PUBMED: 11211889] ">Younossi 2001</a>; <a href="./references#CD011132-bbs2-0005" title="SalmeronJ , DiagoM , AndradeR , PerezR , SolaR , RomeroM , et al. Induction doses of interferon‐alpha‐2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non‐responders to interferon monotherapy: a randomized trial. Journal of Viral Hepatitis2007;14(2):89‐95. ">Salmeron 2007</a>; <a href="./references#CD011132-bbs2-0001" title="AbbasZ , RazaS , HamidS , JafriW . Randomized controlled trial of interferon gamma versus amantadine in combination with interferon alpha and ribavirin for hepatitis C genotype 3 non‐responders and relapsers. Journal of the Pakistan Medical Association2012;62:338‐43. ">Abbas 2012</a>). The method of performing allocation concealment was judged as unclear in two trials (<a href="./references#CD011132-bbs2-0004" title="KhaliliM , DenhamC , PerrilloR . A comparison of combination therapy with interferon and ribavirin vs interferon and amantadine in interferon non‐responders with chronic hepatitis C. Hepatology1999;28(4):169A. KhaliliM , DenhamC , PerrilloR . Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C. American Journal of Gastroenterology2000;95(5):1284‐9. [PUBMED: 10811340] ">Khalili 2000</a>; <a href="./references#CD011132-bbs2-0003" title="HerrineSK , BrownRSJr , BernsteinDE , OndovikMS , LentzE , TeH . Peginterferon alpha‐2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha‐2b plus ribavirin: a pilot study of efficacy and safety. Digestive Diseases and Sciences2005;50(4):719‐26. ">Herrine 2005</a>) and judged as high risk in one trial (<a href="./references#CD011132-bbs2-0002" title="BacosiM , RussoF , DínnocenzoS , SantolamazzaM , MiglioresiL , UrsittiA , et al. Amantadine and interferon in the combined treatment of hepatitis C virus in elderly patients. Hepatology Research2002;22(3):231‐9. ">Bacosi 2002</a>). </p> </section> <section id="CD011132-sec-0068"> <h4 class="title">Blinding (performance bias and detection bias)  </h4> <p>The method of blinding of participants and personnel was adequately described in only one trial (<a href="./references#CD011132-bbs2-0006" title="YounossiZM , MullenKD , ZakkoW , BrandtE , HodnickS , BarnesD , et al. Interferon alpha2B‐ribavirin vs. interferon alpha2B‐amantadine combination in chronic hepatitis C; analyses of a randomized, double‐blind trial. Hepatology1999;30(4):372A. YounossiZM , MullenKD , ZakkoW , BrandtE , HodnickS , EasleyK , et al. Interferon alpha2b and ribavirin vs interferon alpha2b and amantadine for chronic hepatitis C (non‐responder): a multi‐center, randomized, double‐blind trial. Hepatology1998;28(4):284A. YounossiZM , MullenKD , ZakkoW , HodnickS , BrandE , BarnesDS , et al. A randomized, double‐blind controlled trial of interferon alpha‐2b and ribavirin vs. interferon alpha‐2b and amantadine for treatment of chronic hepatitis C non‐responder to interferon monotherapy. Journal of Hepatology2001;34(1):128‐33. [PUBMED: 11211889] ">Younossi 2001</a>). The other five trials were considered to have a high risk of bias in the blinding of participants and personnel domain (<a href="./references#CD011132-sec-0099" title="">Characteristics of included studies</a>). None of the trials adequately described the method of blinding of outcome assessment; thus, six trials were considered as high risk of bias (<a href="./references#CD011132-sec-0099" title="">Characteristics of included studies</a>). This also means that none of the included trials had a low risk of bias according to both blinding of participants and personnel and blinding of outcome assessments (<a href="./references#CD011132-sec-0099" title="">Characteristics of included studies</a>). </p> </section> <section id="CD011132-sec-0069"> <h4 class="title">Incomplete outcome data (attrition bias)  </h4> <p>Incomplete data were addressed adequately in two trials (<a href="./references#CD011132-bbs2-0004" title="KhaliliM , DenhamC , PerrilloR . A comparison of combination therapy with interferon and ribavirin vs interferon and amantadine in interferon non‐responders with chronic hepatitis C. Hepatology1999;28(4):169A. KhaliliM , DenhamC , PerrilloR . Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C. American Journal of Gastroenterology2000;95(5):1284‐9. [PUBMED: 10811340] ">Khalili 2000</a>; <a href="./references#CD011132-bbs2-0001" title="AbbasZ , RazaS , HamidS , JafriW . Randomized controlled trial of interferon gamma versus amantadine in combination with interferon alpha and ribavirin for hepatitis C genotype 3 non‐responders and relapsers. Journal of the Pakistan Medical Association2012;62:338‐43. ">Abbas 2012</a>). In the other four trials, there were risks of incomplete outcome data (<a href="./references#CD011132-sec-0099" title="">Characteristics of included studies</a>). </p> </section> <section id="CD011132-sec-0070"> <h4 class="title">Selective reporting (reporting bias)  </h4> <p>There were risks of selective reporting of outcomes in all six trials (<a href="./references#CD011132-sec-0099" title="">Characteristics of included studies</a>). </p> </section> <section id="CD011132-sec-0071"> <h4 class="title">Other potential sources of bias  </h4> <p>Only one trial did not receive funding or other for‐profit support and was therefore of low risk of bias regarding for‐profit domain (<a href="./references#CD011132-bbs2-0001" title="AbbasZ , RazaS , HamidS , JafriW . Randomized controlled trial of interferon gamma versus amantadine in combination with interferon alpha and ribavirin for hepatitis C genotype 3 non‐responders and relapsers. Journal of the Pakistan Medical Association2012;62:338‐43. ">Abbas 2012</a>). Three trials received funding from the medical industry (<a href="./references#CD011132-bbs2-0006" title="YounossiZM , MullenKD , ZakkoW , BrandtE , HodnickS , BarnesD , et al. Interferon alpha2B‐ribavirin vs. interferon alpha2B‐amantadine combination in chronic hepatitis C; analyses of a randomized, double‐blind trial. Hepatology1999;30(4):372A. YounossiZM , MullenKD , ZakkoW , BrandtE , HodnickS , EasleyK , et al. Interferon alpha2b and ribavirin vs interferon alpha2b and amantadine for chronic hepatitis C (non‐responder): a multi‐center, randomized, double‐blind trial. Hepatology1998;28(4):284A. YounossiZM , MullenKD , ZakkoW , HodnickS , BrandE , BarnesDS , et al. A randomized, double‐blind controlled trial of interferon alpha‐2b and ribavirin vs. interferon alpha‐2b and amantadine for treatment of chronic hepatitis C non‐responder to interferon monotherapy. Journal of Hepatology2001;34(1):128‐33. [PUBMED: 11211889] ">Younossi 2001</a>; <a href="./references#CD011132-bbs2-0003" title="HerrineSK , BrownRSJr , BernsteinDE , OndovikMS , LentzE , TeH . Peginterferon alpha‐2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha‐2b plus ribavirin: a pilot study of efficacy and safety. Digestive Diseases and Sciences2005;50(4):719‐26. ">Herrine 2005</a>; <a href="./references#CD011132-bbs2-0005" title="SalmeronJ , DiagoM , AndradeR , PerezR , SolaR , RomeroM , et al. Induction doses of interferon‐alpha‐2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non‐responders to interferon monotherapy: a randomized trial. Journal of Viral Hepatitis2007;14(2):89‐95. ">Salmeron 2007</a>). It was unclear whether the remaining two trials received funding from the medical industry or other for‐profit support (<a href="./references#CD011132-bbs2-0004" title="KhaliliM , DenhamC , PerrilloR . A comparison of combination therapy with interferon and ribavirin vs interferon and amantadine in interferon non‐responders with chronic hepatitis C. Hepatology1999;28(4):169A. KhaliliM , DenhamC , PerrilloR . Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C. American Journal of Gastroenterology2000;95(5):1284‐9. [PUBMED: 10811340] ">Khalili 2000</a>; <a href="./references#CD011132-bbs2-0002" title="BacosiM , RussoF , DínnocenzoS , SantolamazzaM , MiglioresiL , UrsittiA , et al. Amantadine and interferon in the combined treatment of hepatitis C virus in elderly patients. Hepatology Research2002;22(3):231‐9. ">Bacosi 2002</a>) (<a href="./references#CD011132-sec-0099" title="">Characteristics of included studies</a>). We considered these last five trials as having high risk of bias for the for‐profit bias domain (<a href="#CD011132-fig-0003">Figure 3</a>). </p> <p>There were no baseline differences in any of the trials, except for one in which there was baseline imbalance regarding age (<a href="./references#CD011132-bbs2-0004" title="KhaliliM , DenhamC , PerrilloR . A comparison of combination therapy with interferon and ribavirin vs interferon and amantadine in interferon non‐responders with chronic hepatitis C. Hepatology1999;28(4):169A. KhaliliM , DenhamC , PerrilloR . Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C. American Journal of Gastroenterology2000;95(5):1284‐9. [PUBMED: 10811340] ">Khalili 2000</a>). One trial stopped early due to poor results (<a href="./references#CD011132-bbs2-0005" title="SalmeronJ , DiagoM , AndradeR , PerezR , SolaR , RomeroM , et al. Induction doses of interferon‐alpha‐2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non‐responders to interferon monotherapy: a randomized trial. Journal of Viral Hepatitis2007;14(2):89‐95. ">Salmeron 2007</a>). </p> </section> </section> <section id="CD011132-sec-0072"> <h3 class="title" id="CD011132-sec-0072">Effects of interventions</h3> <p>See: <a href="./full#CD011132-tbl-0001"><b>Summary of findings for the main comparison</b> </a> </p> <section id="CD011132-sec-0073"> <h4 class="title">Amantadine versus ribavirin</h4> <p>Three trials compared amantadine plus interferon‐alpha versus ribavirin plus interferon‐alpha; one trial compared amantadine plus peg interferon‐alpha versus ribavirin plus peg interferon‐alpha. </p> <p><b>Primary outcomes</b> </p> <p><i><b>The composite outcome of all‐cause mortality or liver‐related morbidity</b> </i> </p> <p>Four trials provided information on all‐cause mortality or liver‐related morbidity. The combined outcome measure was zero in both the 216 participants in the amantadine group and the 211 patients in the ribavirin group (<a href="./references#CD011132-fig-0007" title="">Analysis 1.1</a>). We were not able to perform meta‐analyses on these data in RevMan, but with trial sequential analysis and a continuity correction of 0.5, we found no significant differences (fixed‐effect model: risk ratio (RR) 0.98; 95% confidence interval (CI) 0.00 to 248.89). The required information size to detect or reject a relative risk reduction (RRR) of 20% with a between‐trial heterogeneity of 0% is estimated to be 140,645 patients. The actually accrued number of patients was 427, which was only 0.3% of the required information size. </p> <p><i><b>Adverse events</b> </i> </p> <p>We classified adverse events into two groups: number of patients with serious adverse events and number of patients with treatment discontinuation due to any adverse event. </p> <p>Ten patients of 216 (5%) in the amantadine group versus 18 patients of 211 patients (9%) in the ribavirin group were reported with either serious adverse events or treatment discontinuation due to any adverse event (<a href="./references#CD011132-fig-0008" title="">Analysis 1.2</a>). Meta‐analyses showed no statistically significant difference (fixed‐effect model: RR 0.56; 95% CI 0.27 to 1.16; I² = 20%) (<a href="./references#CD011132-fig-0008" title="">Analysis 1.2</a>). </p> <p>As there were no trials with low risk of bias, we performed trial sequential analysis on all included trials reporting on adverse events. Trial sequential analysis of these data showed there was too little information to draw any firm conclusions (<a href="#CD011132-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD011132-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Trial sequential analysis of the random‐effects meta‐analysis of the effect of amantadine versus ribavirin in chronic hepatitis C‐infected patients on number of patients experiencing a serious adverse event or number of patients who had to discontinue treatment due to an adverse event. The trial sequential analysis is performed with a type 1 error of 5% (two‐sided), a power of 80%, an assumed control proportion of number of patients experiencing a serious adverse events or who had to discontinue treatment due to an adverse event of 11%, and an anticipated relative risk reduction (RRR) of 20%. The diversity‐adjusted required information size (DARIS) to detect or reject a RRR of 20% with a between‐trial heterogeneity of 0% is estimated to be 7214 participants. The actually accrued number of participants is 398, which is only 6% of the DARIS. The blue cumulative Z‐curve does not cross the red trial sequential monitoring boundaries for benefit or harm. Therefore, there is no evidence to support that amantadine influences number of patients experiencing a serious adverse event or who had to discontinue treatment due to an adverse event. The cumulative Z‐curve does not reach the futility area (which is not even drawn by the program), demonstrating that further randomised trials may be needed." data-id="CD011132-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial sequential analysis of the random‐effects meta‐analysis of the effect of amantadine versus ribavirin in chronic hepatitis C‐infected patients on number of patients experiencing a serious adverse event or number of patients who had to discontinue treatment due to an adverse event. The trial sequential analysis is performed with a type 1 error of 5% (two‐sided), a power of 80%, an assumed control proportion of number of patients experiencing a serious adverse events or who had to discontinue treatment due to an adverse event of 11%, and an anticipated relative risk reduction (RRR) of 20%. The diversity‐adjusted required information size (DARIS) to detect or reject a RRR of 20% with a between‐trial heterogeneity of 0% is estimated to be 7214 participants. The actually accrued number of participants is 398, which is only 6% of the DARIS. The blue cumulative Z‐curve does not cross the red trial sequential monitoring boundaries for benefit or harm. Therefore, there is no evidence to support that amantadine influences number of patients experiencing a serious adverse event or who had to discontinue treatment due to an adverse event. The cumulative Z‐curve does not reach the futility area (which is not even drawn by the program), demonstrating that further randomised trials may be needed. </p> </div> </div> </div> <p><i><b>Quality of life</b> </i> </p> <p>Only one trial reported on quality of life (<a href="./references#CD011132-bbs2-0006" title="YounossiZM , MullenKD , ZakkoW , BrandtE , HodnickS , BarnesD , et al. Interferon alpha2B‐ribavirin vs. interferon alpha2B‐amantadine combination in chronic hepatitis C; analyses of a randomized, double‐blind trial. Hepatology1999;30(4):372A. YounossiZM , MullenKD , ZakkoW , BrandtE , HodnickS , EasleyK , et al. Interferon alpha2b and ribavirin vs interferon alpha2b and amantadine for chronic hepatitis C (non‐responder): a multi‐center, randomized, double‐blind trial. Hepatology1998;28(4):284A. YounossiZM , MullenKD , ZakkoW , HodnickS , BrandE , BarnesDS , et al. A randomized, double‐blind controlled trial of interferon alpha‐2b and ribavirin vs. interferon alpha‐2b and amantadine for treatment of chronic hepatitis C non‐responder to interferon monotherapy. Journal of Hepatology2001;34(1):128‐33. [PUBMED: 11211889] ">Younossi 2001</a>). Health‐related quality of life (HRQL) was assessed at baseline and every three months using the medical outcome study Short Form‐36 (SF‐36) and a validated liver disease‐specific instrument, Chronic Liver Disease Questionnaire (CLDQ). We were not able to perform meta‐analyses on quality of life due to a lack of valid data. Overall, we found no significant differences between treatment with amantadine versus ribavirin in this trial. </p> <p><b>Secondary outcomes</b> </p> <p><i><b>Failure of serum (or plasma) sustained virological response</b> </i> </p> <p>Four trials provided information on patients who failed to achieve a sustained virological response. In the amantadine group, 206 of 216 patients (95%) did not achieve sustained virological response versus 176 of 211 patients (83%) in the ribavirin group. Meta‐analysis with the fixed‐effect model showed an effect on failure to achieve sustained virological response favouring the ribavirin group: RR 1.14; 95% CI 1.07 to 1.22. This estimated RR with a random‐effects model was similar<i>,</i> with marginally wider confidence intervals including the null: RR 1.15; 95% CI 0.99 to 1.32; I² = 78%) (<a href="./references#CD011132-fig-0009" title="">Analysis 1.3</a>). </p> <p>Three trials reported on failure to achieve sustained virological response in patients treated with amantadine plus interferon‐alpha versus ribavirin plus interferon‐alpha (<a href="./references#CD011132-fig-0009" title="">Analysis 1.3</a>). One‐hundred and seventy‐eight participants of 185 participants (96%) in the amantadine group versus 156 participants of 179 participants (87%) in the ribavirin group failed to achieve sustained virological response. This negative effect of amantadine plus interferon‐alpha compared with ribavirin plus interferon‐alpha, shown by the fixed‐effect meta‐analysis was not observed in the random‐effects model analysis (fixed‐effect model: RR 1.10; 95% CI 1.04 to 1.18; random‐effects model: RR 1.09; 95% CI 0.98 to 1.21; I² = 78%) (<a href="./references#CD011132-fig-0009" title="">Analysis 1.3</a>). </p> <p>Sixty‐three patients were treated in one trial with amantadine plus peg interferon‐alpha versus ribavirin plus peg interferon‐alpha (<a href="./references#CD011132-fig-0009" title="">Analysis 1.3</a>). Twenty‐eight of 31 participants (90%) treated in the amantadine group compared with 20 of 32 participants (63%) in the ribavirin group failed to achieve sustained virological response. Risk ratio for this event was statistically significant comparing amantadine plus peg interferon‐alpha therapy with ribavirin plus peg interferon‐alpha (fixed‐effect model: RR 1.45; 95% CI 1.08 to 1.94) (<a href="./references#CD011132-fig-0009" title="">Analysis 1.3</a>). </p> <p>Analysing the missing data as the <i>best‐worst case scenario</i> in all the four trials comparing amantadine with ribavirin (assuming that participants with unknown status of achieving sustained virological response receiving amantadine did achieve sustained virological response, and that all participants from the ribavirin group with unknown status of achieving sustained virological response did not achieve sustained virological response) reveals no statistically significant differences in effect of amantadine versus ribavirin (fixed‐effect model: RR 0.94; 95% CI 0.86 to 1.03; 427 participants, four trials). Analysing the missing data as the <i>worst‐best case scenario</i> (assuming that participants with unknown status of achieving sustained virological response receiving amantadine did not achieve sustained virological response and that all participants from ribavirin group with unknown status of achieving sustained virological response achieved sustained virological response) shows an effect favouring ribavirin (fixed‐effect model: RR 1.58; 95% CI 1.41 to 1.77; 427 participants, four trials). </p> <p>We performed trial sequential analysis on all the trials. The trial sequential analysis of the combined data supports the finding that ribavirin is superior to amantadine with less failure to achieve sustained virological response (<a href="#CD011132-fig-0005">Figure 5</a>). The result of the trial sequential analysis is shown by the cumulated Z‐curve (blue curve) which crosses the trial sequential boundary (red inward sloping curve). </p> <div class="figure" id="CD011132-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Trial sequential analysis of the random‐effects meta‐analysis of the effect of amantadine versus ribavirin on number of patients with chronic hepatitis C virus infection who failed to achieve a sustained virological response (SVR). The trial sequential analysis is performed with a type 1 error of 5% (two‐sided), a power of 80%, an assumed control proportion of number of patients who failed to achieve an SVR of 83%, and an anticipated relative risk reduction (RRR) of 20%. The diversity‐adjusted required information size (DARIS) to detect or reject a RRR of 20% with a between‐trial heterogeneity of 78% is estimated to be 981 participants. The actually accrued number of participants is 427, which is 44% of the DARIS. The blue cumulative Z‐curve crosses the red trial sequential monitoring boundary for harm. Therefore, there is evidence to support that ribavirin is superior compared with amantadine." data-id="CD011132-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial sequential analysis of the random‐effects meta‐analysis of the effect of amantadine versus ribavirin on number of patients with chronic hepatitis C virus infection who failed to achieve a sustained virological response (SVR). The trial sequential analysis is performed with a type 1 error of 5% (two‐sided), a power of 80%, an assumed control proportion of number of patients who failed to achieve an SVR of 83%, and an anticipated relative risk reduction (RRR) of 20%. The diversity‐adjusted required information size (DARIS) to detect or reject a RRR of 20% with a between‐trial heterogeneity of 78% is estimated to be 981 participants. The actually accrued number of participants is 427, which is 44% of the DARIS. The blue cumulative Z‐curve crosses the red trial sequential monitoring boundary for harm. Therefore, there is evidence to support that ribavirin is superior compared with amantadine. </p> </div> </div> </div> <p><i><b>Failure of end‐of treatment virological response</b> </i> </p> <p>Three trials provided data on participants who failed to achieve end‐of treatment virological response and could be included in the analyses (<a href="./references#CD011132-fig-0010" title="">Analysis 1.4</a>). In the amantadine group, 128 of 157 participants (82%) did not achieve end‐of treatment virological response versus 103 of 152 participants (68%) in the ribavirin group. Meta‐analysis showed that amantadine showed more failure to achieve end‐of treatment virological response compared to ribavirin (fixed‐effect model: RR 1.20; 95% CI 1.05 to 1.36; I² = 32%) (<a href="./references#CD011132-fig-0010" title="">Analysis 1.4</a>). </p> <p>We performed trial sequential analysis on all the three trials. There is no evidence to support that amantadine influences the number of participants who failed to achieve an end‐of treatment virological response (<a href="#CD011132-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD011132-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Trial sequential analysis of the random‐effects meta‐analysis of the effect of amantadine versus ribavirin on number of patients with chronic hepatitis C virus infection who failed to achieve an end‐of treatment virological response. The trial sequential analysis is performed with a type 1 error of 5% (two‐sided), a power of 80%, an assumed control proportion of number of patients who failed to achieve an SVR of 68%, and an anticipated relative risk reduction (RRR) of 20%. The diversity‐adjusted required information size (DARIS) to detect or reject a RRR of 20% with a between‐trial heterogeneity of 32% is estimated to be 594 participants. The actually accrued number of participants is 309, which is 52% of the DARIS. The blue cumulative Z‐curve does not cross the red trial sequential monitoring boundaries for benefit or harm. Therefore, we cannot exclude random error." data-id="CD011132-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial sequential analysis of the random‐effects meta‐analysis of the effect of amantadine versus ribavirin on number of patients with chronic hepatitis C virus infection who failed to achieve an end‐of treatment virological response. The trial sequential analysis is performed with a type 1 error of 5% (two‐sided), a power of 80%, an assumed control proportion of number of patients who failed to achieve an SVR of 68%, and an anticipated relative risk reduction (RRR) of 20%. The diversity‐adjusted required information size (DARIS) to detect or reject a RRR of 20% with a between‐trial heterogeneity of 32% is estimated to be 594 participants. The actually accrued number of participants is 309, which is 52% of the DARIS. The blue cumulative Z‐curve does not cross the red trial sequential monitoring boundaries for benefit or harm. Therefore, we cannot exclude random error. </p> </div> </div> </div> <p>Analysing the data in the <i>best‐worst case scenario</i> regarding missing data (assuming that participants with unknown status of achieving end‐of treatment virological response receiving amantadine did achieve end‐of treatment virological response, and that all participants from the ribavirin group with unknown status of achieving end‐of treatment virological response did not achieve end‐of treatment virological response) reveals no differences in effect estimate; thus, no negative effect of amantadine (fixed‐effect model: RR 0.91; 95% CI 0.78 to 1.07; 309 participants, three trials). Analysing the data in the <i>worst‐best case scenario</i> regarding missing data (assuming that participants with unknown status of achieving end‐of treatment virological response receiving amantadine did not achieve end‐of treatment virological response, and that all participants from control group with unknown status of achieving end‐of treatment virological response did achieve end‐of treatment virological response) reveals a stronger effect favouring ribavirin (fixed‐effect model: RR 2.01; 95% CI 1.64 to 2.46; 309 participants, three trials). </p> <p><i><b>Failure in histological response</b> </i> </p> <p>None of the included trials provided information on the number of participants without improvement of histology. </p> <p><i><b>Failure of normalisation of serum ALT levels at end‐of treatment and at end‐of follow‐up</b> </i> </p> <p>All trials that reported on biochemical response, only reported on ALT levels.</p> <p>Only one trial provided information on failure of normalisation of end‐of treatment biochemical response. In the amantadine group, 13 of 15 participants (87%) did not achieve end‐of treatment biochemical response versus 6 of 14 participants (43%) in the ribavirin group. Meta‐analyses showed that amantadine resulted in more participants without normalisation of ALT serum levels at end‐of treatment compared with ribavirin (fixed‐effect model: RR 2.02; 95% CI 1.07 to 3.82) (<a href="./references#CD011132-fig-0011" title="">Analysis 1.5</a>). </p> <p>In two trials, 41 participants of 46 participants (89%) treated with amantadine compared with 31 of 46 participants (67%) in the ribavirin group failed to achieve end‐of follow‐up biochemical response (<a href="./references#CD011132-fig-0012" title="">Analysis 1.6</a>). Meta‐analysis (fixed‐effect model; RR 1.31; 95% CI 1.05 to 1.63; I² = 12%) showed that amantadine more often failed to achieve end‐of follow‐up biochemical response compared to ribavirin (<a href="./references#CD011132-fig-0012" title="">Analysis 1.6</a>). </p> </section> <section id="CD011132-sec-0074"> <h4 class="title">Amantadine versus mycophenolate mofetil</h4> <p>Only one trial provided information on the comparison amantadine versus mycophenolate mofetil (<a href="./references#CD011132-bbs2-0003" title="HerrineSK , BrownRSJr , BernsteinDE , OndovikMS , LentzE , TeH . Peginterferon alpha‐2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha‐2b plus ribavirin: a pilot study of efficacy and safety. Digestive Diseases and Sciences2005;50(4):719‐26. ">Herrine 2005</a>). The included trial reported on 31 participants in the amantadine group versus 29 participants in the mycophenolate mofetil group. </p> <p>The all‐cause mortality or liver‐related morbidity was zero in both intervention arms (<a href="./references#CD011132-fig-0013" title="">Analysis 2.1</a>). </p> <p>Five participants of 31 (16%) in the amantadine group versus five participants of 29 participants (17%) in the mycophenolate mofetil group were reported with either serious adverse events or treatment discontinuation due to any adverse event (<a href="./references#CD011132-fig-0014" title="">Analysis 2.2</a>). There were no significant differences between the groups (fixed‐effect model: RR 0.94; 95% CI 0.30 to 2.90) (<a href="./references#CD011132-fig-0014" title="">Analysis 2.2</a>). The required information size to detect or reject a RRR of 20% with a between‐trial heterogeneity of 14% is estimated to be 4093 participants. The actually accrued number of participants is 60, which is only 1% of the required information size. </p> <p>Twenty‐eight participants (90%) failed to achieve sustained virological response in the amantadine group versus 24 participants (83%) in the mycophenolate mofetil group. There was no significant difference in effect (fixed‐effect model: RR 1.09; 95% CI 0.89 to 1.34) (<a href="./references#CD011132-fig-0015" title="">Analysis 2.3</a>). The required information size to detect or reject a RRR of 20% with a between‐trial heterogeneity of 87% is estimated to be 1661 participants. The actually accrued number of participants is 60, which is only 4% of the required information size. </p> <p>There was a significant negative effect of amantadine on failure to achieve end‐of treatment virological response (fixed‐effect model: RR 2.10; 95% CI 1.09 to 4.08). In the amantadine group, 18 of 31 participants (58%) did not achieve end‐of treatment virological response versus 8 of 29 participants (28%) in the mycophenolate mofetil group (<a href="./references#CD011132-fig-0016" title="">Analysis 2.4</a>). Trial sequential analysis showed a required information size of 4017 participants. The actually accrued number of participants is 60, which is only 1% of the required information size. </p> <p>The included trial did not provide information on quality of life, histological response, and normalisation of ALT at end‐of treatment. </p> <p>Twenty‐six participants treated with amantadine (84%) compared with 23 participants treated with mycophenolate mofetil (79%) failed to achieve end‐of follow‐up biochemical response (<a href="./references#CD011132-fig-0017" title="">Analysis 2.5</a>). Meta‐analyses showed no statistically significant difference (fixed‐effect model: RR 1.06; 95% CI 0.83 to 1.35) (<a href="./references#CD011132-fig-0017" title="">Analysis 2.5</a>). </p> <p>Due to the limited number of participants, we were unable to perform any of the remaining planned sensitivity analysis or funnel plot analysis. </p> </section> <section id="CD011132-sec-0075"> <h4 class="title">Amantadine versus interferon‐alpha</h4> <p>One trial reported on the comparison amantadine versus interferon‐alpha (<a href="./references#CD011132-bbs2-0002" title="BacosiM , RussoF , DínnocenzoS , SantolamazzaM , MiglioresiL , UrsittiA , et al. Amantadine and interferon in the combined treatment of hepatitis C virus in elderly patients. Hepatology Research2002;22(3):231‐9. ">Bacosi 2002</a>). The included trial reported on 42 participants in the amantadine group versus 39 participants in the interferon‐alpha group. </p> <p>The included trial did not provide information on all‐cause mortality, liver‐related morbidity, quality of life, or histological response. </p> <p>Zero participants of 42 (0%) in the amantadine group versus 3 participants of 39 participants (8%) in the interferon‐alpha group were reported with either serious adverse events or treatment discontinuation due to any adverse event (<a href="./references#CD011132-fig-0018" title="">Analysis 3.1</a>). The required information size to detect or reject a RRR of 20% with a between‐trial heterogeneity of 0% is estimated to be 8539 participants. The actually accrued number of participants is 81, which is only 1% of the required information size. </p> <p>Thirty‐five participants (83%) failed to achieve sustained virological response in the amantadine group versus 30 participants (77%) in the interferon‐alpha group, which showed no significant difference in effect (fixed‐effect model: RR 1.08; 95% CI 0.87 to 1.35) (<a href="./references#CD011132-fig-0019" title="">Analysis 3.2</a>). The required information size to detect or reject a RRR of 20% with a between‐trial heterogeneity of 81% is estimated to be 1484 participants. The actually accrued number of participants is 81, which is only 5% of the required information size. </p> <p>Regarding failure to achieve end‐of treatment virological response, there were no significant differences in effect between amantadine and interferon‐alpha (fixed‐effect model: RR 1.25; 95% CI 0.96 to 1.62). In the amantadine group, 35 of 42 participants (83%) did not achieve end‐of treatment virological response versus 26 of 39 participants (67%) in the interferon‐alpha group (<a href="./references#CD011132-fig-0020" title="">Analysis 3.3</a>). Trial sequential analysis showed a required information size of 1745 participants. The actually accrued number of participants is 81, which is only 5% of the required information size. </p> <p>In the amantadine group, 21 of 42 participants (50%) did not achieve end‐of treatment biochemical response versus 22 of 39 participants (56%) in the interferon‐alpha group. Meta‐analyses showed no significant difference in the number of participants without normalisation of ALT serum levels at end‐of treatment compared amantadine with interferon‐alpha (fixed‐effect model: RR 0.89; 95% CI 0.59 to 1.33) (<a href="./references#CD011132-fig-0021" title="">Analysis 3.4</a>). Trial sequential analysis showed a required information size of 1252 participants. The actually accrued number of participants is 81, which is only 6% of the required information size. </p> <p>Twenty‐five participants (60%) treated with amantadine compared with 26 participants (67%) in the interferon‐alpha group failed to achieve end‐of follow‐up biochemical response (<a href="./references#CD011132-fig-0022" title="">Analysis 3.5</a>). Meta‐analyses showed no statistically significant difference (fixed‐effect model: RR 0.89; 95% CI 0.64 to 1.25) (<a href="./references#CD011132-fig-0022" title="">Analysis 3.5</a>). Trial sequential analysis showed a required information size of 1074 participants. The actually accrued number of participants is 81, which is only 8% of the required information size. </p> <p>Due to the limited number of participants, we were unable to perform any of the remaining sensitivity analysis, or funnel plot analysis. </p> </section> <section id="CD011132-sec-0076"> <h4 class="title">Amantadine versus interferon‐gamma</h4> <p>One trial provided information on the comparison amantadine versus interferon‐gamma (<a href="./references#CD011132-bbs2-0001" title="AbbasZ , RazaS , HamidS , JafriW . Randomized controlled trial of interferon gamma versus amantadine in combination with interferon alpha and ribavirin for hepatitis C genotype 3 non‐responders and relapsers. Journal of the Pakistan Medical Association2012;62:338‐43. ">Abbas 2012</a>). This trial reported on 22 participants in both the amantadine group and the interferon‐gamma group. </p> <p>The all‐cause mortality or liver‐related morbidity was zero in both intervention arms (<a href="./references#CD011132-fig-0023" title="">Analysis 4.1</a>). The required information size to detect or reject a RRR of 20% with a between‐trial heterogeneity of 0% is estimated to be 70,005 participants. The actually accrued number of participants is 44, which is only 0.06% of the required information size. </p> <p>Two participants in the amantadine group (9%) versus zero participants (0%) in the interferon‐gamma group were reported with either serious adverse events or treatment discontinuation due to any adverse event (<a href="./references#CD011132-fig-0024" title="">Analysis 4.2</a>). The required information size to detect or reject a RRR of 20% with a between‐trial heterogeneity of 50% is estimated to be 140,010 participants. The actually accrued number of participants is 44, which is only 0.03% of the required information size. </p> <p>Sixteen participants failed to achieve sustained virological response in the amantadine group versus 11 participants in the interferon‐gamma group. There was no significant effect of amantadine compared with interferon‐gamma (fixed‐effect model: RR 1.45; 95% CI 0.89 to 2.37) (<a href="./references#CD011132-fig-0025" title="">Analysis 4.3</a>). The required information size to detect or reject a RRR of 20% with a between‐trial heterogeneity of 66% is estimated to be 2288 participants. The actually accrued number of participants is 44, which is only 2% of the required information size. </p> <p>Also, there was no significant effect of amantadine compared with interferon‐gamma on failure to achieve end‐of treatment virological response (fixed‐effect model: RR 1.36; 95% CI 0.82 to 2.26). In the amantadine group, 15 participants (68%) did not achieve end‐of treatment virological response versus 11 participants (50%) in the interferon‐gamma group (<a href="./references#CD011132-fig-0026" title="">Analysis 4.4</a>). The required information size to detect or reject a RRR of 20% with a between‐trial heterogeneity of 63% is estimated to be 2102 participants. The actually accrued number of participants is 44, which is only 2% of the required information size. </p> <p>The included trial did not provide information on the outcome measures: quality of life and histological response. </p> <p>In the amantadine group, 15 participants (68%) did not achieve end‐of treatment biochemical response versus 11 participants (50%) in the interferon‐gamma group. Meta‐analyses showed no significant difference in effect comparing amantadine with interferon‐gamma (fixed‐effect model: RR 1.36; 95% CI 0.82 to 2.26) (<a href="./references#CD011132-fig-0027" title="">Analysis 4.5</a>). Again, trial sequential analysis showed a required information size of 2102 participants. The actually accrued number of participants is 44. This is only 2% of the required information size. </p> <p>Sixteen participants (73%) treated with amantadine compared with 11 participants (50%) in the interferon‐gamma group failed to achieve end‐of follow‐up biochemical response (<a href="./references#CD011132-fig-0028" title="">Analysis 4.6</a>). Meta‐analyses showed no differences (fixed‐effect model: RR 1.45; 95% CI 0.89 to 2.37) (<a href="./references#CD011132-fig-0028" title="">Analysis 4.6</a>). Trial sequential analysis showed a required information size of 2288 participants. The actually accrued number of participants is 44, which is only 2% of the required information size. </p> <p>Due to the limited number of participants, we were unable to perform any of the remaining planned trial sequential analysis, sensitivity analysis, or funnel plot analysis. </p> </section> <section id="CD011132-sec-0077"> <h4 class="title">Amantadine versus other antiviral‐drugs</h4> <p>For completeness we have also meta‐analysed data from all comparisons together in order to answer the question: which is best, amantadine or other antivirals? The heterogenous group of other antivirals seemed superior. </p> </section> <section id="CD011132-sec-0078"> <h4 class="title">Summary of finding<i>s</i> </h4> <p>The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) 'Summary of findings' table (<a href="./references#CD011132-bbs2-0046" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical Research Ed.)2008;336(7650):924‐6. [PUBMED: 18436948] ">Guyatt 2008</a>) is shown in <a href="./full#CD011132-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011132-sec-0079" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011132-sec-0079"></div> <section id="CD011132-sec-0080"> <h3 class="title" id="CD011132-sec-0080">Summary of main results  </h3> <p>We included six randomised clinical trials with 581 participants that assessed the benefits and harms of amantadine versus other antiviral drugs for the treatment of chronic hepatitis C virus. Amantadine was compared with four other antiviral drugs: ribavirin, mycophenolate mofetil, interferon‐alpha, or interferon‐gamma. The effect of amantadine was evaluated in four different treatment strategies: monotherapy of amantadine, combination therapy of amantadine with interferon‐alpha, combination therapy of amantadine plus interferon‐alpha and ribavirin, and combination therapy of amantadine plus peg interferon‐alpha. All trials had high risks of bias. </p> <p>This systematic review did not show any benefit of amantadine on all‐cause mortality or liver‐related morbidity. </p> <p>Furthermore, our systematic review also showed that amantadine for participants with chronic hepatitis C virus is not associated with an increase or a reduction of adverse events, defined by the number of participants who experienced a serious adverse event or who had to discontinue treatment due to an adverse event. These results are confirmed by trial sequential analyses. </p> <p>When comparing amantadine versus ribavirin, amantadine seems inferior as the proportion of participants who failed to achieve sustained virological response was larger in the amantadine group. This finding was confirmed by a trial sequential analysis. However, when comparing amantadine with the other three antiviral drugs, we did not demonstrate that participants treated with amantadine had more failure in achieving sustained virological response. These findings could be due to type II errors or bias. Moreover, amantadine did not show to have decreased the overall proportion of participants who failed to achieve end‐of treatment virological response. Again, type II errors or bias should be considered. </p> <p>Unfortunately, we were not able to identify any benefits of amantadine on quality of life and histology because none of the included trials reported on quality of life or failure of histological improvement. We found a disadvantage of amantadine compared with ribavirin on biochemical end‐of treatment and on end‐of follow‐up responses. </p> </section> <section id="CD011132-sec-0081"> <h3 class="title" id="CD011132-sec-0081">Overall completeness and applicability of evidence  </h3> <p>This systematic review examined the evidence from six included randomised clinical trials for the use of treatment of hepatitis C virus. Despite efforts to obtain additional information from the trial authors, we could not obtain all relevant data, hence not all trials reported on all of our predefined outcomes. </p> <p>Due to the limited number of included trials and participants, we were not able to perform subgroup analyses according to whether a patient had already received a previous antiviral therapy for hepatitis C virus, e.g., naive participants, relapsers, or non‐responders, and if so, which treatment he/she had received. Five trials reported adequately on all‐cause mortality or liver‐related morbidity, and all six trials reported on serious adverse events and treatment discontinuation due to an adverse event. None of the included trials provided information on quality of life. Six trials reported on our first secondary outcome: failure of achieving sustained virological response. Five trials reported on failure of end‐of treatment virological response. No trial provided information on failure in histological improvement, three trials reported on failure of biochemical response at end‐of treatment, and four trials reported on failure of biochemical response at end‐of follow‐up. </p> <p>It is questionable whether the included participants are representative for the current practice. All trials included participants with positive serum HCV RNA. However, there is heterogeneity among trials due to different disease severity of participants at entry, differences according to genotype (five trials included a mixture of genotypes), and differences regarding previous antiviral treatment. Concerning sex and age, the trials seem representative for current clinical care; more than 67% of the included participants were men and all trials included adult participants. None of the trials included participants with hepatitis B virus or HIV co‐infection. Accordingly, we lack data on co‐infected patients. </p> </section> <section id="CD011132-sec-0082"> <h3 class="title" id="CD011132-sec-0082">Quality of the evidence  </h3> <p>We conducted this review according to <i>The Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011132-bbs2-0049" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) and the Cochrane Hepato‐Biliary Group Module (<a href="./references#CD011132-bbs2-0044" title="GluudC , NikolovaD , KlingenbergSL , AlexakisN , Als‐NielsenB , ColliA , et al. Cochrane Hepato‐Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2014, Issue 1. Art. No.: LIVER. ">Gluud 2014</a>). The results of our meta‐analysis, however, are only as strong as the quality of primary trials included. </p> <p>The main limitation in the design and implementation is the lack of clarity of the generation of allocation sequence, concealment of allocation, and blinding. Of the included trials, only one (17%) reported adequate allocation sequence generation; only three (50%) adequately reported on allocation concealment; and none reported blinding. Two trials (33%) adequately addressed incomplete data, but none of the trials reported on all clinically relevant and reasonably expected outcomes. Also, one trial (17%) appeared to be free of other components that could put them at risk of bias. Accordingly, all trials were with high risk of bias. It is surprising to see that none of the trials were considered as having low risk of bias, in spite of the repeated calls for improved trial quality both within and outside hepatology (<a href="./references#CD011132-bbs2-0083" title="SchultzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273:408‐12. ">Schultz 1995</a>; <a href="./references#CD011132-bbs2-0042" title="GluudC , NikolovaD . Quality assessment of reports on clinical trials in the Journal of Hepatology. Journal of Hepatology1998;29(2):321‐7. ">Gluud 1998</a>; <a href="./references#CD011132-bbs2-0058" title="KjaergardLL , NikolovaD , GluudC . Randomized clinical trials in Hepatology: predictors of quality. Hepatology1999;30(5):1134‐8. ">Kjaergard 1999</a>; <a href="./references#CD011132-bbs2-0073" title="NeedlemanI . CONSORT. Consolidated Standards of Reporting Trials. British Dental Journal1999;186(5):207. ">Needleman 1999</a>; <a href="./references#CD011132-bbs2-0059" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomised trials in meta‐analyses. Annals of Internal Medicine2001;135:982‐9. ">Kjaergard 2001</a>; <a href="./references#CD011132-bbs2-0103" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ (Clinical Research Ed.)2008;336(7644):601‐5. ">Wood 2008</a>; <a href="./references#CD011132-bbs2-0081" title="SavovićJ , JonesH , AltmanD , HarrisR , JuniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta‐epidemiological studies. Health Technology Assessment (Winchester, England)2012;16(35):1‐82. [PUBMED: 22989478] ">Savović 2012</a>). Also, other bias domains had high risk of bias. Patients, patient organisations, and other stakeholders do not get unbiased research before the several calls for unbiased clinical research is followed by physicians, regulatory authorities, and industry. </p> <p>Regarding precision of our results, some outcomes of the included trials in our meta‐analysis include few participants and few events, and thus the confidence intervals around the estimate of effect are large. </p> <p>All trials measured sustained virological response which is currently the most commonly used surrogate outcome measure of benefit. Recent large cohort studies showed a positive correlation between the presence of viraemia and mortality (<a href="./references#CD011132-bbs2-0024" title="ButtAA , WangX , MooreCG . Effect of hepatitis C virus and its treatment on survival. Hepatology2009;50(2):387‐92. [PUBMED: 19591128] ">Butt 2009</a>; <a href="./references#CD011132-bbs2-0099" title="UtoH , StuverSO , HayashiK , KumagaiK , SasakiF , KanmuraS , et al. Increased rate of death related to presence of viremia among hepatitis C virus antibody‐positive subjects in a community‐based cohort study. Hepatology2009;50(2):393‐9. [PUBMED: 19585614] ">Uto 2009</a>). However, sustained virological response is still only a putative (unvalidated) surrogate outcome for the patient‐relevant intervention effect of antivirals (<a href="./references#CD011132-bbs2-0043" title="GluudC , BrokJ , GongY , KoretzRL . Hepatology may have problems with putative surrogate outcome measures. Journal of Hepatology2007;46(4):734‐42. [PUBMED: 17316871] ">Gluud 2007</a>; <a href="./references#CD011132-bbs2-0045" title="GurusamyKS , WilsonE , KoretzRL , AllenVB , DavidsonBR , BurroughsAK , et al. Is sustained virological response a marker of treatment efficacy in patients with chronic hepatitis C viral infection with no response of relapse to previous antiviral intervention?. PLoS ONE2013;8(12):e83313. ">Gurusamy 2013</a>; <a href="./references#CD011132-bbs2-0062" title="KoretzRL , PleguezueloM , ArvanitiV , BaenaPB , CiriaR , GurusamyKS , et al. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD003617.pub2] ">Koretz 2013</a>). Because randomised clinical trials need to inform clinical practice, clinical outcomes such as the risk of liver failure, hepatocellular carcinoma, mortality, and quality of life would be of greater interest to patients and clinicians. Such measures nevertheless require a follow‐up of maybe up to five years. Currently, no randomised clinical trials assessing aminoadamantanes are of such long duration. </p> </section> <section id="CD011132-sec-0083"> <h3 class="title" id="CD011132-sec-0083">Potential biases in the review process  </h3> <p>In this systematic review, a comprehensive literature search was performed. As far as we know, we have found all the evidence available. A potential limitation of our literature search may be that we have not specifically searched for trials in the grey literature which may have introduced a slight risk of bias into our meta‐analysis (<a href="./references#CD011132-bbs2-0039" title="EggerM , JuniP , BartlettC , HolensteinF , SterneJ . How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. Health Technology Assessment2003;7(1):1‐76. ">Egger 2003</a>). However, the bias is unlikely to influence our results in a beneficial way as trials found in grey literature rarely report beneficial effects (<a href="./references#CD011132-bbs2-0051" title="HopewellS , McDonaldS , ClarkeM , EggerM . Grey literature in meta‐analyses of randomized trials of health care interventions. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.MR000010.pub3; PUBMED: 17443631] ">Hopewell 2007</a>). </p> <p>We only included six trials, in which four different antiviral regimens (ribavirin, mycophenolate mofetil, interferon‐alpha, or interferon‐gamma) were used as comparator drugs. Also, most of the included trials are of a relatively small size. This increases the risk of providing a more unrealistic estimate of the intervention effects due to bias (systematic errors) or chance (random errors) (<a href="./references#CD011132-bbs2-0056" title="KeusF , WetterslevJ , GluudC , vanLaarhovenCJ . Evidence at a glance: error matrix approach for overviewing available evidence. BMC Medical Research Methodology2010;10:90. [PUBMED: 20920306] ">Keus 2010</a>). Risk of bias is known to have an impact on the estimated intervention effect, with trials with high risk of bias tending to overestimate beneficial intervention effects and underestimating harmful effects (<a href="./references#CD011132-bbs2-0083" title="SchultzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273:408‐12. ">Schultz 1995</a>; <a href="./references#CD011132-bbs2-0071" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet1998;352:609‐13. ">Moher 1998</a>; <a href="./references#CD011132-bbs2-0059" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomised trials in meta‐analyses. Annals of Internal Medicine2001;135:982‐9. ">Kjaergard 2001</a>; <a href="./references#CD011132-bbs2-0103" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ (Clinical Research Ed.)2008;336(7644):601‐5. ">Wood 2008</a>; <a href="./references#CD011132-bbs2-0069" title="LundhA , SismondoS , LexchinJ , BusuiocOA , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2; PUBMED: 23235689] ">Lundh 2012</a>; <a href="./references#CD011132-bbs2-0081" title="SavovićJ , JonesH , AltmanD , HarrisR , JuniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta‐epidemiological studies. Health Technology Assessment (Winchester, England)2012;16(35):1‐82. [PUBMED: 22989478] ">Savović 2012</a>; <a href="./references#CD011132-bbs2-0082" title="SavovićJ , JonesHE , AltmanDG , HarrisRJ , JuniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429‐38. [PUBMED: 22945832] ">Savović 2012a</a>). We could not divide the analysis for all outcomes into high risk of bias trials and low risk of bias trials to reveal any influence of bias on the effect estimates of our outcomes, because all six trials were considered to have high risk of bias. </p> <p>No statistical signs of publication bias and other bias were observed.</p> <p>This review meta‐analysed data for all‐cause mortality or liver‐related morbidity from five trials involving 500 participants. We also meta‐analysed data for serious adverse events or treatment discontinuation due to an adverse event from six trials involving 581 participants. The median length of trial duration was 12 months (two trials had a trial duration of six months), the median length of follow‐up was six months (one trial had a follow‐up of 12 months). For our primary outcome all‐cause mortality or liver‐related morbidity, this is not sufficiently long considering that the estimated median time in which hepatitis C virus progresses to cirrhosis is 15 years to 50 years (<a href="./references#CD011132-bbs2-0061" title="KoretzRL , AbbeyH , ColemanE , GitnickG . Non‐A, non‐B post‐transfusion hepatitis. Lookin back in the second decade. Annals of Internal Medicine1993;119(2):110‐5. ">Koretz 1993</a>; <a href="./references#CD011132-bbs2-0055" title="Kenny‐WalshE . Clinical outcomes after hepatitis C infection from contaminated anti‐D immune globulin. Irish Hepatology Research Group. New England Journal of Medicine1999;340(16):1228‐33. ">Kenny‐Walsh 1999</a>; <a href="./references#CD011132-bbs2-0085" title='SeeffLB . The history of the "natural history" of hepatitis C (1968‐2009). Liver International2009;29 Suppl 1:89‐99. '>Seeff 2009</a>). Therefore, it is difficult to detect a significant difference on all‐cause mortality and liver‐related morbidity based on these trials. If aminoadamantanes should have an effect on morbidity and mortality, one prerequisite would be that it significantly affected virological load. However, we were unable to extract viral data to show that this was the case. </p> <p>We used trial sequential analysis (<a href="./references#CD011132-bbs2-0029" title="Copenhagen Trial Unit. TSA ‐ Trial Sequential Analysis. ctu.dk/tsa/ 2011 (accessed 19 March 2014). ">CTU 2011</a>; <a href="./references#CD011132-bbs2-0096" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual forTrial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 20 March 2014). ">Thorlund 2011</a>) to control the risk of random errors which is higher when data come from trials with small sample sizes (<a href="./references#CD011132-bbs2-0100" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. ">Wetterslev 2008</a>). The trial sequential analysis on the outcome serious adverse events or treatment discontinuation due to an adverse event showed no significant effect estimate applying both the random‐effects and fixed‐effect models in participants treated with amantadine. The trial sequential analysis on the secondary outcome measure sustained virological response applied for amantadine compared with ribavirin demonstrated a negative effect on the number of participants who failed to achieve sustained virological response in participants treated with amantadine. Thus, random errors seem to have been excluded for this comparison, but systematic errors may remain. </p> <p>Heterogeneity among trials might be due to differences in dose, duration and type of interferon‐alpha, or peg interferon‐alpha. The inclusion of interferon‐alpha as well as peg interferon‐alpha with pharmacokinetic differences might have influenced the observed outcomes and comparability of results with earlier publications. Also, different definitions of non‐responders were used, such as non‐responder to previous interferon‐alpha therapy alone or non‐responder to combination therapy of interferon‐alpha with ribavirin. Furthermore, there could be heterogeneity among trials due to disease severity of participants at entry and differences according to genotype, both of which can affect the sustained virological response rates. To reflect our concern about heterogeneity, we conducted all analyses using both the fixed‐effect model and random‐effects model. We only presented the results of the fixed‐effect model if the results of the two models did not differ. Subgroup analyses of the pre‐defined covariates trial risk of bias, genotype distribution, previous antiviral treatment, and degree of liver disease could not be performed because of the lack of trials that reported on these variables. </p> </section> <section id="CD011132-sec-0084"> <h3 class="title" id="CD011132-sec-0084">Agreements and disagreements with other studies or reviews  </h3> <p>Less than about 10% of all hepatitis C virus infected patients will develop end‐stage liver disease. Overall, we found that amantadine did not show any benefit on all‐cause mortality or liver‐related morbidity. Most trials report on the surrogate outcome sustained virological response, but as already mentioned, we do not know if sustained virological response results in less mortality or morbidity (<a href="./references#CD011132-bbs2-0043" title="GluudC , BrokJ , GongY , KoretzRL . Hepatology may have problems with putative surrogate outcome measures. Journal of Hepatology2007;46(4):734‐42. [PUBMED: 17316871] ">Gluud 2007</a>; <a href="./references#CD011132-bbs2-0022" title="BrokJ , GluudLL , GluudC . Ribavirin monotherapy for chronic hepatitis C. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD005527.pub2] ">Brok 2009</a>; <a href="./references#CD011132-bbs2-0045" title="GurusamyKS , WilsonE , KoretzRL , AllenVB , DavidsonBR , BurroughsAK , et al. Is sustained virological response a marker of treatment efficacy in patients with chronic hepatitis C viral infection with no response of relapse to previous antiviral intervention?. PLoS ONE2013;8(12):e83313. ">Gurusamy 2013</a>; <a href="./references#CD011132-bbs2-0062" title="KoretzRL , PleguezueloM , ArvanitiV , BaenaPB , CiriaR , GurusamyKS , et al. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD003617.pub2] ">Koretz 2013</a>; <a href="./references#CD011132-bbs2-0047" title="HauserG , AwadT , BrokJ , ThorlundK , ŠtimacD , MabroukM , et al. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD005441.pub3] ">Hauser 2014</a>; <a href="./references#CD011132-bbs2-0048" title="HauserG , AwadT , ThorlundK , ŠtimacD , MabroukM , GluudC . Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD005642.pub3] ">Hauser 2014a</a>). </p> <p>Also, considering failure in achieving sustained virological response, we found that amantadine did not show any benefit. On the contrary, amantadine showed less effect compared with ribavirin, a finding which was supported by the trial sequential analyses. This result is in accordance with the main findings of a published meta‐analysis (<a href="./references#CD011132-bbs2-0025" title="ChenJ , ShiJ , XieWF , ZengX , LinY . Meta‐analysis: amantadine may lower the efficacy of pegylated interferon plus ribavirin in treatment‐naive hepatitis C genotype 1 patients. International Journal of Infectious Diseases2012;16(10):e748‐e752. ">Chen 2012</a>) which suggests that there is no beneficial effect of adding amantadine to peg interferon‐alpha plus ribavirin in naive hepatitis C virus genotype 1 patients. Our findings are contrary to the main findings of another meta‐analyses (<a href="./references#CD011132-bbs2-0033" title="DeltenreP , HenrionJ , CanvaV , DharancyS , TexierF , LouvetA , et al. Evaluation of amantadine in chronic hepatitis C: a meta‐analysis. Journal of Hepatology2004;41(3):462‐73. [PUBMED: 15336450] ">Deltenre 2004</a>) which suggested a role for amantadine in non‐responder patients. Furthermore, our results are also in contrast with another review which suggests that there may be a limited role for combination therapy in naive patients (<a href="./references#CD011132-bbs2-0068" title="LimJK , WootenD , SiegelR , CheungRC . Amantadine in treatment of chronic hepatitis C virus infection?. Journal of Viral Hepatitis2005;12(5):445‐55. ">Lim 2005</a>). </p> <p>We have no evidence from randomised trials on long‐term (&gt; one year) effects of amantadine on our primary outcomes. Long‐term effects would in particular be relevant for outcomes like all‐cause mortality or liver‐related morbidity. </p> <p>Amantadine was generally well tolerated. We observed that amantadine was associated with non‐serious adverse events and almost all trials reported in general similar frequencies and severities of adverse events in both amantadine groups versus control groups. This result is in accordance with a Cochrane review about amantadine and rimantadine for influenza A in children and the elderly (<a href="./references#CD011132-bbs2-0016" title="Alves GalvãoMG , Rocha Crispino SantosMA , Alves de CunhaAJL . Amantadine and rimantadine for influenza A in children and the elderly. Cochrane Database of Systematic Reviews2012, Issue 1. [DOI: 10.1002/14651858.CD002745.pub3] ">Alves Galvao 2012</a>). This result is also somewhat comparable to two other Cochrane reviews. The review on amantadine and rimantadine in influenza A in adults showed significantly more adverse effects in patients receiving amantadine compared to placebo, but no increased risk of serious adverse events (<a href="./references#CD011132-bbs2-0054" title="JeffersonT , DemichellV , DiPietrantonjC , RivettiD . Amantadine and rimantadine for influenza A in adults. Cochrane Database of Systematic Reviews2012, Issue 7. [DOI: 10.1002/14651858.CD001169.pub3] ">Jefferson 2012</a>). The second review reported on amantadine in Parkinson's disease and found that there is not enough evidence from trials about the effects of amantadine for people with Parkinson’s disease, and that adverse events in trials so far have not been severe (<a href="./references#CD011132-bbs2-0028" title="CrosbyN , DeaneKH , ClarkeCE . Amantadine in Parkinson's disease. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD003468] ">Crosby 2009</a>). In our analysis, amantadine was administered with interferon‐alpha or peg interferon‐alpha with or without ribavirin, except for one trial. Interferon‐alpha‐based therapy is typically associated with haematologic complications (i.e., neutropenia, thrombocytopenia), neuropsychiatric complications (i.e., memory and concentration loss, visual disturbances, headaches, depression, irritability), flu‐like symptoms, hormonal complications (i.e., hypothyroidism, hyperthyroidism), gastrointestinal complications (i.e., nausea, vomiting, weight loss), and dermatologic complications (i.e., eczema, alopecia). The most well‐known adverse effect of ribavirin is a dose‐dependent haemolytic anaemia, but gastrointestinal adverse effects such as nausea are also reported (<a href="./references#CD011132-bbs2-0027" title="ChutaputtiA . Adverse effects and other safety aspects of the hepatitis C antivirals. Journal of Gastroenterology and Hepatology2000;15(Suppl):E156‐E163. ">Chutaputti 2000</a>; <a href="./references#CD011132-bbs2-0091" title="SozaA , EverhartJE , GhanyMG , DooE , HellerT , PromratK , et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology2002;36(5):1273‐9. ">Soza 2002</a>; <a href="./references#CD011132-bbs2-0092" title="SulkowskiMS , WassermanR , BrooksL , BallL , GishR . Changes in haemoglobin during interferon alpha‐2b plus ribavirin combination therapy for chronic hepatitis C virus infection. Journal of Viral Hepatitis2004;11(3):243‐50. ">Sulkowski 2004</a>). In conclusion, both interferon‐alpha and ribavirin have a variety and severity of adverse events, which may make it hard to detect less severe adverse events of amantadine. We cannot exclude less severe adverse events from amantadine, for example gastro‐intestinal symptoms and insomnia. </p> <p>Regarding tolerance of amantadine, we have to take into consideration the doses of amantadine. All included trials used an amantadine dose of 200 mg per day. One randomised trial that evaluated the safety and toxicity of amantadine in patients with chronic hepatitis C virus also investigated the maximum tolerable dose of amantadine (<a href="./references#CD011132-bbs2-0090" title="SmithJP , RileyTR3rd , BingamanS , MaugerDT . Amantadine therapy for chronic hepatitis C: a dose escalation study. American Journal of Gastroenterology2004;99(6):1099‐104. ">Smith 2004a</a>). They reported an increase in biochemical response with higher daily doses of amantadine from 200 mg per day up to 500 mg per day in monotherapy. However, no statistically difference was found in ALT values between those receiving 300 mg of amantadine or those receiving higher doses of amantadine. Also, increasing the amantadine dose did not result in more patients achieving sustained virological response comparing 200 mg per day with 300 mg to 500 mg per day (<a href="./references#CD011132-bbs2-0090" title="SmithJP , RileyTR3rd , BingamanS , MaugerDT . Amantadine therapy for chronic hepatitis C: a dose escalation study. American Journal of Gastroenterology2004;99(6):1099‐104. ">Smith 2004a</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011132-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Flow diagram." data-id="CD011132-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/full#CD011132-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011132-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/full#CD011132-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011132-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/full#CD011132-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis of the random‐effects meta‐analysis of the effect of amantadine versus ribavirin in chronic hepatitis C‐infected patients on number of patients experiencing a serious adverse event or number of patients who had to discontinue treatment due to an adverse event. The trial sequential analysis is performed with a type 1 error of 5% (two‐sided), a power of 80%, an assumed control proportion of number of patients experiencing a serious adverse events or who had to discontinue treatment due to an adverse event of 11%, and an anticipated relative risk reduction (RRR) of 20%. The diversity‐adjusted required information size (DARIS) to detect or reject a RRR of 20% with a between‐trial heterogeneity of 0% is estimated to be 7214 participants. The actually accrued number of participants is 398, which is only 6% of the DARIS. The blue cumulative Z‐curve does not cross the red trial sequential monitoring boundaries for benefit or harm. Therefore, there is no evidence to support that amantadine influences number of patients experiencing a serious adverse event or who had to discontinue treatment due to an adverse event. The cumulative Z‐curve does not reach the futility area (which is not even drawn by the program), demonstrating that further randomised trials may be needed." data-id="CD011132-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Trial sequential analysis of the random‐effects meta‐analysis of the effect of amantadine versus ribavirin in chronic hepatitis C‐infected patients on number of patients experiencing a serious adverse event or number of patients who had to discontinue treatment due to an adverse event. The trial sequential analysis is performed with a type 1 error of 5% (two‐sided), a power of 80%, an assumed control proportion of number of patients experiencing a serious adverse events or who had to discontinue treatment due to an adverse event of 11%, and an anticipated relative risk reduction (RRR) of 20%. The diversity‐adjusted required information size (DARIS) to detect or reject a RRR of 20% with a between‐trial heterogeneity of 0% is estimated to be 7214 participants. The actually accrued number of participants is 398, which is only 6% of the DARIS. The blue cumulative Z‐curve does not cross the red trial sequential monitoring boundaries for benefit or harm. Therefore, there is no evidence to support that amantadine influences number of patients experiencing a serious adverse event or who had to discontinue treatment due to an adverse event. The cumulative Z‐curve does not reach the futility area (which is not even drawn by the program), demonstrating that further randomised trials may be needed. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/full#CD011132-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis of the random‐effects meta‐analysis of the effect of amantadine versus ribavirin on number of patients with chronic hepatitis C virus infection who failed to achieve a sustained virological response (SVR). The trial sequential analysis is performed with a type 1 error of 5% (two‐sided), a power of 80%, an assumed control proportion of number of patients who failed to achieve an SVR of 83%, and an anticipated relative risk reduction (RRR) of 20%. The diversity‐adjusted required information size (DARIS) to detect or reject a RRR of 20% with a between‐trial heterogeneity of 78% is estimated to be 981 participants. The actually accrued number of participants is 427, which is 44% of the DARIS. The blue cumulative Z‐curve crosses the red trial sequential monitoring boundary for harm. Therefore, there is evidence to support that ribavirin is superior compared with amantadine." data-id="CD011132-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Trial sequential analysis of the random‐effects meta‐analysis of the effect of amantadine versus ribavirin on number of patients with chronic hepatitis C virus infection who failed to achieve a sustained virological response (SVR). The trial sequential analysis is performed with a type 1 error of 5% (two‐sided), a power of 80%, an assumed control proportion of number of patients who failed to achieve an SVR of 83%, and an anticipated relative risk reduction (RRR) of 20%. The diversity‐adjusted required information size (DARIS) to detect or reject a RRR of 20% with a between‐trial heterogeneity of 78% is estimated to be 981 participants. The actually accrued number of participants is 427, which is 44% of the DARIS. The blue cumulative Z‐curve crosses the red trial sequential monitoring boundary for harm. Therefore, there is evidence to support that ribavirin is superior compared with amantadine. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/full#CD011132-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis of the random‐effects meta‐analysis of the effect of amantadine versus ribavirin on number of patients with chronic hepatitis C virus infection who failed to achieve an end‐of treatment virological response. The trial sequential analysis is performed with a type 1 error of 5% (two‐sided), a power of 80%, an assumed control proportion of number of patients who failed to achieve an SVR of 68%, and an anticipated relative risk reduction (RRR) of 20%. The diversity‐adjusted required information size (DARIS) to detect or reject a RRR of 20% with a between‐trial heterogeneity of 32% is estimated to be 594 participants. The actually accrued number of participants is 309, which is 52% of the DARIS. The blue cumulative Z‐curve does not cross the red trial sequential monitoring boundaries for benefit or harm. Therefore, we cannot exclude random error." data-id="CD011132-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Trial sequential analysis of the random‐effects meta‐analysis of the effect of amantadine versus ribavirin on number of patients with chronic hepatitis C virus infection who failed to achieve an end‐of treatment virological response. The trial sequential analysis is performed with a type 1 error of 5% (two‐sided), a power of 80%, an assumed control proportion of number of patients who failed to achieve an SVR of 68%, and an anticipated relative risk reduction (RRR) of 20%. The diversity‐adjusted required information size (DARIS) to detect or reject a RRR of 20% with a between‐trial heterogeneity of 32% is estimated to be 594 participants. The actually accrued number of participants is 309, which is 52% of the DARIS. The blue cumulative Z‐curve does not cross the red trial sequential monitoring boundaries for benefit or harm. Therefore, we cannot exclude random error. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/full#CD011132-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Amantadine versus ribavirin, Outcome 1 All‐cause mortality or liver‐related morbidity." data-id="CD011132-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Amantadine versus ribavirin, Outcome 1 All‐cause mortality or liver‐related morbidity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Amantadine versus ribavirin, Outcome 2 Adverse events." data-id="CD011132-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Amantadine versus ribavirin, Outcome 2 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Amantadine versus ribavirin, Outcome 3 Failure of sustained virological response." data-id="CD011132-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Amantadine versus ribavirin, Outcome 3 Failure of sustained virological response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Amantadine versus ribavirin, Outcome 4 Failure of end of treatment virological response." data-id="CD011132-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Amantadine versus ribavirin, Outcome 4 Failure of end of treatment virological response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Amantadine versus ribavirin, Outcome 5 Failure of normalisation of ALT at end of treatment." data-id="CD011132-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Amantadine versus ribavirin, Outcome 5 Failure of normalisation of ALT at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Amantadine versus ribavirin, Outcome 6 Failure of normalisation of ALT at end of follow‐up." data-id="CD011132-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Amantadine versus ribavirin, Outcome 6 Failure of normalisation of ALT at end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Amantadine versus mycophenolate mofetil, Outcome 1 All‐cause mortality or liver‐related morbidity." data-id="CD011132-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Amantadine versus mycophenolate mofetil, Outcome 1 All‐cause mortality or liver‐related morbidity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Amantadine versus mycophenolate mofetil, Outcome 2 Adverse events." data-id="CD011132-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Amantadine versus mycophenolate mofetil, Outcome 2 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Amantadine versus mycophenolate mofetil, Outcome 3 Failure of sustained virological response." data-id="CD011132-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Amantadine versus mycophenolate mofetil, Outcome 3 Failure of sustained virological response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Amantadine versus mycophenolate mofetil, Outcome 4 Failure of end of treatment virological response." data-id="CD011132-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Amantadine versus mycophenolate mofetil, Outcome 4 Failure of end of treatment virological response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Amantadine versus mycophenolate mofetil, Outcome 5 Failure of normalisation of ALT at end of follow‐up." data-id="CD011132-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Amantadine versus mycophenolate mofetil, Outcome 5 Failure of normalisation of ALT at end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Amantadine versus interferon‐alpha, Outcome 1 Adverse events." data-id="CD011132-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Amantadine versus interferon‐alpha, Outcome 1 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Amantadine versus interferon‐alpha, Outcome 2 Failure of sustained virological response." data-id="CD011132-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Amantadine versus interferon‐alpha, Outcome 2 Failure of sustained virological response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Amantadine versus interferon‐alpha, Outcome 3 Failure of end of treatment virological response." data-id="CD011132-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Amantadine versus interferon‐alpha, Outcome 3 Failure of end of treatment virological response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Amantadine versus interferon‐alpha, Outcome 4 Failure of normalisation of ALT at end of treatment." data-id="CD011132-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Amantadine versus interferon‐alpha, Outcome 4 Failure of normalisation of ALT at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Amantadine versus interferon‐alpha, Outcome 5 Failure of normalisation of ALT at end of follow‐up." data-id="CD011132-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Amantadine versus interferon‐alpha, Outcome 5 Failure of normalisation of ALT at end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Amantadine versus interferon‐gamma, Outcome 1 All‐cause mortality or liver‐related morbidity." data-id="CD011132-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Amantadine versus interferon‐gamma, Outcome 1 All‐cause mortality or liver‐related morbidity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Amantadine versus interferon‐gamma, Outcome 2 Adverse events." data-id="CD011132-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Amantadine versus interferon‐gamma, Outcome 2 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Amantadine versus interferon‐gamma, Outcome 3 Failure of sustained virological response." data-id="CD011132-fig-0025" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Amantadine versus interferon‐gamma, Outcome 3 Failure of sustained virological response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Amantadine versus interferon‐gamma, Outcome 4 Failure of end of treatment virological response." data-id="CD011132-fig-0026" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Amantadine versus interferon‐gamma, Outcome 4 Failure of end of treatment virological response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Amantadine versus interferon‐gamma, Outcome 5 Failure of normalisation of ALT at end of treatment." data-id="CD011132-fig-0027" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Amantadine versus interferon‐gamma, Outcome 5 Failure of normalisation of ALT at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Amantadine versus interferon‐gamma, Outcome 6 Failure of normalisation of ALT at end of follow‐up." data-id="CD011132-fig-0028" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Amantadine versus interferon‐gamma, Outcome 6 Failure of normalisation of ALT at end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Amantadine versus other antiviral drugs, Outcome 1 All‐cause mortality or liver‐related morbidity." data-id="CD011132-fig-0029" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Amantadine versus other antiviral drugs, Outcome 1 All‐cause mortality or liver‐related morbidity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Amantadine versus other antiviral drugs, Outcome 2 Adverse events." data-id="CD011132-fig-0030" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Amantadine versus other antiviral drugs, Outcome 2 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Amantadine versus other antiviral drugs, Outcome 3 Failure of sustained virological response." data-id="CD011132-fig-0031" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Amantadine versus other antiviral drugs, Outcome 3 Failure of sustained virological response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Amantadine versus other antiviral drugs, Outcome 4 Failure of end of treatment virological response." data-id="CD011132-fig-0032" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Amantadine versus other antiviral drugs, Outcome 4 Failure of end of treatment virological response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Amantadine versus other antiviral drugs, Outcome 5 Failure of normalisation of ALT at end of treatment." data-id="CD011132-fig-0033" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Amantadine versus other antiviral drugs, Outcome 5 Failure of normalisation of ALT at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Amantadine versus other antiviral drugs, Outcome 6 Failure of normalisation of ALT at end of follow‐up." data-id="CD011132-fig-0034" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Amantadine versus other antiviral drugs, Outcome 6 Failure of normalisation of ALT at end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Sensitivity analysis, Outcome 1 Failure of sustained virological response." data-id="CD011132-fig-0035" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Sensitivity analysis, Outcome 1 Failure of sustained virological response.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011132-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/urn:x-wiley:14651858:media:CD011132:CD011132-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_t/tCD011132-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Sensitivity analysis, Outcome 2 Failure of end of treatment virological response." data-id="CD011132-fig-0036" src="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Sensitivity analysis, Outcome 2 Failure of end of treatment virological response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/media/CDSR/CD011132/image_n/nCD011132-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011132-tbl-0001"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Aminoadamantanes compared with ribavirin for chronic hepatitis C</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with chronic hepatitis C. </p> <p><b>Settings:</b> mainly outpatients in tertiary and teaching hospitals. </p> <p><b>Intervention:</b> aminoadamantanes. </p> <p><b>Comparison:</b> ribavirin. </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ribavirin</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Aminoadamantanes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality or liver‐related morbidity</b> </p> <p>Follow‐up: 12‐24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.98</b> </p> <p>(0.00 to 248.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>427<br/> (4 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 12‐24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.56</b> </p> <p>(0.27 to 1.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>427<br/> (4 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>86 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>47 per 1000</b> <br/> (23 to 98) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Failure of sustained virological response</b> </p> <p>Absence of clearance of HCV RNA from the blood 6 months after treatment</p> <p>Follow‐up: 12‐24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.14</b> </p> <p>(1.07 to 1.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>427<br/> (4 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>low<sup>2</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>835 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>954 per 1000</b> <br/> (896 to 1021) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Failure of end of treatment virological response</b> </p> <p>Absence of clearance of HCV RNA from the blood at end of treatment</p> <p>Follow‐up: 12‐24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.20</b> </p> <p>(1.05 to 1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>309</p> <p>(3 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>2</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>678 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>816 per 1000</b> <br/> (714 to 925) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Failure of normalisation of ALT at end of treatment</b> </p> <p>Follow‐up: 12‐24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.02</b> </p> <p>(1.07 to 3.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>29<br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>429 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>867 per 1000</b> <br/> (460 to 1640) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Failure of normalisation of ALT at end of follow‐up</b> </p> <p>Follow‐up: 12‐24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.31</b> </p> <p>(1.05 to 1.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>92<br/> (2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>674 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>892 per 1000</b> <br/> (715 to 1110) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ALT:</b> alanine aminotransferase; <b>CI:</b> confidence interval; <b>HCV:</b> hepatitis C virus; <b>RNA:</b> ribonucleic acid; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>1. Quality of the evidence was downgraded based on the risk of bias, imprecision of results, inconsistency of results.<br/> 2. Quality of the evidence was downgraded based on the risk of bias and inconsistency of results. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/full#CD011132-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011132-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of characteristics of the included trials</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial duration (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Follow‐up duration (months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Amantadine versus ribavirin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011132-bbs2-0004" title="KhaliliM , DenhamC , PerrilloR . A comparison of combination therapy with interferon and ribavirin vs interferon and amantadine in interferon non‐responders with chronic hepatitis C. Hepatology1999;28(4):169A. KhaliliM , DenhamC , PerrilloR . Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C. American Journal of Gastroenterology2000;95(5):1284‐9. [PUBMED: 10811340] ">Khalili 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011132-bbs2-0006" title="YounossiZM , MullenKD , ZakkoW , BrandtE , HodnickS , BarnesD , et al. Interferon alpha2B‐ribavirin vs. interferon alpha2B‐amantadine combination in chronic hepatitis C; analyses of a randomized, double‐blind trial. Hepatology1999;30(4):372A. YounossiZM , MullenKD , ZakkoW , BrandtE , HodnickS , EasleyK , et al. Interferon alpha2b and ribavirin vs interferon alpha2b and amantadine for chronic hepatitis C (non‐responder): a multi‐center, randomized, double‐blind trial. Hepatology1998;28(4):284A. YounossiZM , MullenKD , ZakkoW , HodnickS , BrandE , BarnesDS , et al. A randomized, double‐blind controlled trial of interferon alpha‐2b and ribavirin vs. interferon alpha‐2b and amantadine for treatment of chronic hepatitis C non‐responder to interferon monotherapy. Journal of Hepatology2001;34(1):128‐33. [PUBMED: 11211889] ">Younossi 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011132-bbs2-0003" title="HerrineSK , BrownRSJr , BernsteinDE , OndovikMS , LentzE , TeH . Peginterferon alpha‐2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha‐2b plus ribavirin: a pilot study of efficacy and safety. Digestive Diseases and Sciences2005;50(4):719‐26. ">Herrine 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011132-bbs2-0005" title="SalmeronJ , DiagoM , AndradeR , PerezR , SolaR , RomeroM , et al. Induction doses of interferon‐alpha‐2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non‐responders to interferon monotherapy: a randomized trial. Journal of Viral Hepatitis2007;14(2):89‐95. ">Salmeron 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Amantadine versus mycophenolate mofetil</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011132-bbs2-0003" title="HerrineSK , BrownRSJr , BernsteinDE , OndovikMS , LentzE , TeH . Peginterferon alpha‐2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha‐2b plus ribavirin: a pilot study of efficacy and safety. Digestive Diseases and Sciences2005;50(4):719‐26. ">Herrine 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Amantadine versus interferon‐alpha</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011132-bbs2-0002" title="BacosiM , RussoF , DínnocenzoS , SantolamazzaM , MiglioresiL , UrsittiA , et al. Amantadine and interferon in the combined treatment of hepatitis C virus in elderly patients. Hepatology Research2002;22(3):231‐9. ">Bacosi 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Amantadine versus interferon‐gamma</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011132-bbs2-0001" title="AbbasZ , RazaS , HamidS , JafriW . Randomized controlled trial of interferon gamma versus amantadine in combination with interferon alpha and ribavirin for hepatitis C genotype 3 non‐responders and relapsers. Journal of the Pakistan Medical Association2012;62:338‐43. ">Abbas 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of characteristics of the included trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/full#CD011132-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011132-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Amantadine versus ribavirin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality or liver‐related morbidity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Amantadine plus interferon‐alpha versus ribavirin plus interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>364</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Amantadine plus peg interferon‐alpha versus ribavirin plus peg interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.27, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Amantadine plus interferon‐alpha versus ribavirin plus interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>364</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.14, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Amantadine plus peg interferon‐alpha versus ribavirin plus peg interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.33, 3.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Failure of sustained virological response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.07, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Amantadine plus interferon‐alpha versus ribavirin plus interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>364</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [1.04, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Amantadine plus peg interferon‐alpha versus ribavirin plus peg interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [1.08, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Failure of end of treatment virological response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [1.05, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Amantadine plus interferon‐alpha versus ribavirin plus interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [1.03, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Amantadine plus peg interferon‐alpha versus ribavirin plus peg interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.85, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Failure of normalisation of ALT at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [1.07, 3.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Amantadine plus interferon‐alpha versus ribavirin plus interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [1.07, 3.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Failure of normalisation of ALT at end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [1.05, 1.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Amantadine plus interferon‐alpha versus ribavirin plus interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.91, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Amantadine plus peg interferon‐alpha versus ribavirin plus peg interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [1.02, 1.96]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Amantadine versus ribavirin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011132-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Amantadine versus mycophenolate mofetil</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality or liver‐related morbidity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Amantadine plus peg interferon‐alpha versus mycophenolate mofetil plus peg interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.30, 2.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Amantadine plus peg interferon‐alpha versus mycophenolate mofetil plus peg interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.30, 2.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Failure of sustained virological response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.89, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Amantadine plus peg interferon‐alpha versus mycophenolate mofetil plus peg interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.89, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Failure of end of treatment virological response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.10 [1.09, 4.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Amantadine plus peg interferon‐alpha versus mycophenolate mofetil plus peg interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.10 [1.09, 4.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Failure of normalisation of ALT at end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.83, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Amantadine plus peg interferon‐alpha versus mycophenolate mofetil plus peg interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.83, 1.35]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Amantadine versus mycophenolate mofetil</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011132-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Amantadine versus interferon‐alpha</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.01, 2.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Amantadine versus interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.01, 2.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Failure of sustained virological response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.87, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Amantadine versus interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.87, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Failure of end of treatment virological response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.96, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Amantadine versus interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.96, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Failure of normalisation of ALT at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.59, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Amantadine versus interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.59, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Failure of normalisation of ALT at end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.64, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Amantadine versus interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.64, 1.25]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Amantadine versus interferon‐alpha</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011132-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Amantadine versus interferon‐gamma</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality or liver‐related morbidity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Amantadine plus interferon‐alpha and ribavirin versus interferon‐gamma plus interferon‐alpha and ribavirin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.25, 98.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Amantadine plus interferon‐alpha and ribavirin versus interferon‐gamma plus interferon‐alpha and ribavirin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.25, 98.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Failure of sustained virological response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.89, 2.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Amantadine plus interferon‐alpha and ribavirin versus interferon‐gamma plus interferon‐alpha and ribavirin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.89, 2.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Failure of end of treatment virological response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.82, 2.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Amantadine plus interferon‐alpha and ribavirin versus interferon‐gamma plus interferon‐alpha and ribavirin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.82, 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Failure of normalisation of ALT at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.82, 2.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Amantadine plus interferon‐alpha and ribavirin versus interferon‐gamma plus interferon‐alpha and ribavirin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.82, 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Failure of normalisation of ALT at end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.89, 2.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Amantadine plus interferon‐alpha and ribavirin versus interferon‐gamma plus interferon‐alpha and ribavirin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.89, 2.37]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Amantadine versus interferon‐gamma</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011132-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Amantadine versus other antiviral drugs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality or liver‐related morbidity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>531</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Amantadine plus interferon‐alpha versus ribavirin plus interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>364</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Amantadine plus peg interferon‐alpha versus ribavirin plus peg interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Amantadine plus peg interferon‐alpha versus mycophenolate mofetil plus peg interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Amantadine versus interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Amantadine plus interferon‐alpha and ribavirin versus interferon‐gamma plus interferon‐alpha and ribavirin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>612</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.37, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Amantadine plus interferon‐alpha versus ribavirin plus interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>364</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.14, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Amantadine plus peg interferon‐alpha versus ribavirin plus peg interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.33, 3.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Amantadine plus peg interferon‐alpha versus mycophenolate mofetil plus peg interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.30, 2.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Amantadine versus interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.01, 2.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Amantadine plus interferon‐alpha and ribavirin versus interferon‐gamma plus interferon‐alpha and ribavirin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.25, 98.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Failure of sustained virological response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>612</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.07, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Amantadine plus interferon‐alpha versus ribavirin plus interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>364</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [1.04, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Amantadine plus peg interferon‐alpha versus ribavirin plus peg interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [1.08, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Amantadine plus peg interferon‐alpha versus mycophenolate mofetil plus peg interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.89, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Amantadine versus interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.87, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Amantadine plus interferon‐alpha and ribavirin versus interferon‐gamma plus interferon‐alpha and ribavirin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.89, 2.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Failure of end of treatment virological response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [1.13, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Amantadine plus interferon‐alpha versus ribavirin plus interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [1.03, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Amantadine plus peg interferon‐alpha versus ribavirin plus peg interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.85, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Amantadine plus peg interferon‐alpha versus mycophenolate mofetil plus peg interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.10 [1.09, 4.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Amantadine versus interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.96, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Amantadine plus interferon‐alpha and ribavirin versus interferon‐gamma plus interferon‐alpha and ribavirin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.82, 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Failure of normalisation of ALT at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.90, 1.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Amantadine plus interferon‐alpha versus ribavirin plus interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [1.07, 3.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Amantadine versus interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.59, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Amantadine plus interferon‐alpha and ribavirin versus interferon‐gamma plus interferon‐alpha and ribavirin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.82, 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Failure of normalisation of ALT at end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.99, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Amantadine plus interferon‐alpha versus ribavirin plus interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.91, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Amantadine plus peg interferon‐alpha versus ribavirin plus peg interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [1.02, 1.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Amantadine plus peg interferon‐alpha versus mycophenolate mofetil plus peg interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.83, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Amantadine versus interferon‐alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.64, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Amantadine plus interferon‐alpha and ribavirin versus interferon‐gamma plus interferon‐alpha and ribavirin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.89, 2.37]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Amantadine versus other antiviral drugs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011132-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Sensitivity analysis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure of sustained virological response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>854</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [1.13, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Best‐worst: Amantadine versus ribavirin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.86, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Worst‐best: Amantadine versus ribavirin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [1.41, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Failure of end of treatment virological response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>618</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [1.17, 1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Best‐worst: Amantadine versus ribavirin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.78, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Worst‐best: Amantadine versus ribavirin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.01 [1.64, 2.46]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Sensitivity analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011132.pub2/references#CD011132-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011132.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011132-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011132-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011132-note-0001">Français</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011132\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011132\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011132\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011132\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011132\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011132\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011132\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011132\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011132\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011132\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011132\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011132\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011132\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011132\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011132\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011132\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011132\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011132\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=qy4lqFNF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011132.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011132.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011132.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011132.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011132.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728899779"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011132.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728899782"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011132.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ecfbd997d9368',t:'MTc0MDcyODkwMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 